Down Syndrome: Neuropsychological phenotype and mitochondrial DNA by Lomartire, Laura
  
Alma Mater Studiorum – Università di Bologna 
 
DOTTORATO DI RICERCA IN 
Oncologia e Patologia Sperimentale: progetto n. 2 
Ciclo XXIV 
06/A2 
MED/04 
Dipartimento di Patologia Sperimentale 
 
 
Down Syndrome: Neuropsychological phenotype 
and mitochondrial DNA 
 
Dott.ssa LAURA LOMARTIRE 
 
 
 
 
Coordinatore:             Relatore: 
Prof. SANDRO GRILLI        Prof. CLAUDIO FRANCESCHI 
 
 
 
Esame finale anno 2012 
1 
 
INDEX 
 
 
INDEX .................................................................................................... 1 
ABBREVIATIONS ................................................................................. 4 
PREFACE .............................................................................................. 6 
DOWN SYNDROME .............................................................................. 7 
1. The Down Syndrome: epidemiological aspects ............................................................................... 7 
2. The Down Syndrome: cytogenetic aspects ...................................................................................... 8 
3. The Down Syndrome: pathogenic aspects ....................................................................................... 9 
3.1 Phenotypic variability ................................................................................................................ 11 
3.2 Congenital Heart Defects and Gastrointestinal System Malformations ............................. 12 
3.3 Immune and Hematopoietic Systems ...................................................................................... 12 
3.4 Central Nervous System ............................................................................................................ 13 
DOWN SYNDROME AND ACCELERATED AGING .......................... 15 
1. Introduction ......................................................................................................................................... 15 
1.1 Skin and Hair changes ............................................................................................................... 15 
1.2 Vision and Hearing Impairments .............................................................................................. 16 
1.3 Seizure disorder .......................................................................................................................... 16 
1.4 Thyroid dysfunction ................................................................................................................... 16 
1.5 Immune system changes........................................................................................................... 17 
1.6 CNS changes ............................................................................................................................... 17 
2. Alzheimer’s disease in Down Syndrome ......................................................................................... 18 
2.1 APP gene...................................................................................................................................... 18 
2.2 APOE gene ................................................................................................................................... 19 
2.3 Oxidative stress .......................................................................................................................... 20 
2.4 The “gene-dosage” and the “two-hit” hypothesis................................................................. 22 
3. Theories on aging ............................................................................................................................... 23 
3.1 The evolutionary theories.......................................................................................................... 24 
3.2 The Network Theory ................................................................................................................... 25 
3.3 The Remodeling Theory ............................................................................................................ 26 
2 
 
3.4 mtDNA damage and the mitochondrial theory of aging ....................................................... 28 
3.5 Mitochondrial dysfunction and DS .......................................................................................... 30 
MITOCHONDRIAL GENETICS ........................................................... 32 
1. Introduction ......................................................................................................................................... 32 
2. Mitochondrial DNA .............................................................................................................................. 33 
3. MtDNA variability ................................................................................................................................ 36 
3.1 Haplogroups ................................................................................................................................ 36 
3.2 Point mutations of mtDNA......................................................................................................... 38 
3.3 A special case: C150T ................................................................................................................ 40 
AIM OF THE STUDY ........................................................................... 44 
MATERIALS AND METHODS ............................................................ 45 
1. Samples ................................................................................................................................................ 45 
2. General protocol ................................................................................................................................. 45 
3. Purification of DNA ............................................................................................................................. 46 
4. Quantification of DNA ........................................................................................................................ 48 
5. Complete sequencing of mtDNA ...................................................................................................... 49 
5.1 Analysis at ABI3730 sequencer ................................................................................................ 53 
5.2 Automated procedure ................................................................................................................ 55 
6. Assignment of subhaplogroups ....................................................................................................... 56 
7. Complete sequencing of mtDNA by Long-PCR .............................................................................. 56 
8. Analysis of heteroplasmy .................................................................................................................. 58 
8.1 Quantitative analysis .................................................................................................................. 59 
9. APOE genotyping................................................................................................................................ 60 
10. Statistical analysis .............................................................................................................................. 62 
RESULTS ............................................................................................ 63 
1. Samples ................................................................................................................................................ 63 
2. Distribution of haplogroups .............................................................................................................. 64 
3. Analysis of mtDNA mutations ........................................................................................................... 66 
4. Analysis of heteroplasmy .................................................................................................................. 78 
5. APOE genotype ................................................................................................................................... 79 
DISCUSSION AND CONCLUSIONS .................................................. 83 
3 
 
APPENDIX ........................................................................................... 87 
REFERENCES .................................................................................... 92 
 
4 
 
ABBREVIATIONS 
 
 
Aβ β-amyloid 
AD Alzheimer‘s Disease 
APOE Apolipoprotein E 
APP Amyloid Precursor Protein 
ATPase ATP synthase 
BACE2 β-site APP-cleaving 2 enzyme 
BF Bromophenol Blue 
CBS Cystathionin β-synthase 
CNS Central Nervous System 
CO Cytochrome c Oxidase 
CPEO Chronic Progressive External Ophthalmoplegia 
CR Control Region 
CSB Conserved Sequence Block 
D-loop Displacement Loop 
DS Down Syndrome 
DSCR Down Syndrome critical Region 
dsDNA Double-Strand DNA 
DSM Down Syndrome Mother 
DSS Down Syndrome Sibling 
DYRK1A Dualspecificity Tyrosine-(Y)-Phosphorylation Kinase 1A 
ETC Electron Transport Chain 
GARS–AIRS–GART 
Complex Glycinamide Ribonucleotide Synthase–Aminoimidazole Ribonucleotide 
Synthase–Glycinamide Formyl Transferase 
GATA 1 Globin Transcription Factor 1 
Hsa21 Human Chromosome 21 
HSP Heat Shock Protein 
HVS Hypervariable Sequence 
ID Intellectual Disability 
IQ Intelligence Quotient 
KSS Kearns-Sayre Syndrome 
LDL Low-Density Lipoprotein 
LTD Long-Term Depression 
LTP Long-Term Potentiation 
MERRF Myoclonic Epilepsy and Ragged Red Fiber 
miRNA Micro-RNA 
mtDNA Mitochondrial DNA 
mtTFA Mitochondrial Transcription Factor A 
5 
 
ND NADH Dehydrogenase 
nDNA Nuclear DNA 
OH Origin of H-strand Replication 
OL Origin of L-strand Replication 
OS Oxidative Stress 
OXPHOS Oxidative Phosphorylation 
PARP Poly (ADP-ribose) Polymerase 
PH H-strand Promoter 
PL L-strand Promoter 
RCAN1 Regulator of Calcineurin 1 
REST RE1-Silencing Transcription Factor 
ROS Reactive Oxygen Species 
RRF Red Ragged Fibers 
SOD-1 Cu2+/Zn2+ Superoxide Dismutase 
XC Xilene Cyanol  
YBP Years Before Present 
 
 
6 
 
PREFACE 
 
 
Down Syndrome is the most known autosomal trisomy, due to the presence in three copies of 
chromosome 21. Many studies were designed to identify phenotypic and clinical consequences related to 
the triple gene dosage. However, the general conclusion is a senescent phenotype; in particular, the most 
features of physiological aging, such as skin and hair changes, vision and hearing impairments, thyroid 
dysfunction, Alzheimer-like dementia, congenital heart defects, gastrointestinal malformations, immune 
system changes, appear in DS earlier than in normal age-matched subjects. 
The only established risk factor for the DS is advanced maternal age, responsible for changes in the 
meiosis of oocytes, in particular the meiotic nondisjunction of chromosome 21. In this process mitochondria 
play an important role since mitochondrial dysfunction, due to a variety of extrinsic and intrinsic influences, 
can profoundly influence the level of ATP generation in oocytes, required for a correct chromosomal 
segregation. 
The aim of this study is to analyze the mtDNA and APOE genotypes of DS subjects and compare 
with their mothers and siblings of age-gender comparable, in order to identify any differences that might 
justify the early neurocognitive decline observed in DS. 
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Chapter 1 
 
DOWN SYNDROME 
 
 
1. The Down Syndrome: epidemiological aspects 
Down Syndrome (DS), or trisomy 21, is the most common and known chromosomal anomaly, 
caused by the presence in three copies of chromosome 21 (Hsa21) or, more rarely, parts of it, following a 
meiotic non-disjunction during ovogenesis. The origin of the supernumerary chromosome 21 is maternal in 
93% of cases, while in 7% of cases is due to nondisjunction of the chromosome of paternal origin. 
In 95% of cases, trisomy 21 is in free form, which is the presence of the entire surplus Hsa21 not 
translocated to other chromosomes; in most cases, the trisomy 21 is homogeneous, i.e. it is present in all 
cells analyzed, while in 3,5% of patients trisomy 21 is in the mosaic, only present in some cells. In 4% of 
cases, the trisomy 21 is due to a translocation of Hsa21 on another chromosome (Robertsonian 
translocation), and finally in 1% of patients trisomy 21 is partial. From the clinical point of view the effect is 
the same, while the reproductive consequences (risk of recurrence) for the parental couple are related to 
the type of cytogenetic trisomy 21. Therefore for the diagnosis of DS is needed the presence of trisomy 21 
in association with the clinical picture. 
The estimated incidence of DS is approximately 1/700-1/1000 live births, with a slight predominance 
in males [Canfield et al. 2006]: the annual number of children born with DS appears to be decreasing, 
mainly because of the voluntary interruption of pregnancy (VIP); VIP logs show a progressive increase in 
the years of voluntary terminations for DS and it is estimated that the percentage of abortions after 
diagnosis of DS is about 58%. 
The only established risk factor for the DS is advanced maternal age, responsible for changes in the 
process of meiosis (M) of oocytes, in particular the meiotic nondisjunction of Hsa21 [Ghosh et al. 2009]; 
during both the phase I (MI) and the phase II (MII), the error rate varies according to maternal age: they are 
lower among mothers aged <19 and ≥ 40 years and higher in the intermediate group and, in women aged 
≥ 40 years, the MII nondisjunction is more common [Allen et al. 2009]. 
Trisomy 21 results in a high risk of spontaneous abortion and neonatal morbidity and mortality: in the 
period between the time of chorionic villus sampling and the period of gestation, the percentage of 
miscarriages is 43%, while between the time of amniocentesis and the term of gestation is 23% [Morris et 
al. 1999]. The literature has shown a correlation between maternal age and a directly proportional 
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incidence of spontaneous abortion of fetuses with DS, with the increasing of the incidence of spontaneous 
abortions associated to the increasing maternal age (from 23% for mothers at the age of 25 years to 45% 
for those 45 years) [Savva et al. 2006]. 
In recent years the quality and life expectancy of patients with DS were significantly improved, 
thanks to continued progress in medical treatment: in particular has increased survival in early childhood, 
following the improvement of cardiac surgery, and most people with DS reach over 60 years of age; life 
expectancy for males is greater of about 3.3 years compared to females; life extension, however, lead to an 
increase of percentage of diseases associated with aging [Glasson et al. 2002]. 
 
 
2. The Down Syndrome: cytogenetic aspects 
Many studies were designed to identify phenotypic and clinical consequences related to the triple 
gene dosage due to trisomy 21. 
Chromosome 21 has been completely sequenced in the late ‗90s [Hattori et al. 2000]. The genes of 
Hsa21 so far identified are more than 400 [Gardiner et al. 2006], 20-50 of which are located at the terminal 
part of the long arm (21q22.2), the so-called Down Syndrome Critical Region (DSCR). Although this 
number is high, it is not an intractable one, and the number of genes that are involved in DS is likely to be 
considerably less than their total number on the chromosome. The main question is whether the DS 
phenotype is determined by only a few genes with a major phenotypic effect or whether the phenotype 
results from the interaction of several genes of modest effect. Based on studies in animal models, there is 
reason to hope that the former might be the case. 
Furthermore DS is a disorder of gene dosage in which the genes that are involved are normal and 
their gene products are also normal. The genetic abnormality is, therefore, quantitative rather than 
qualitative and involves the production of increased amounts of the products of the genes on chromosome 
21. The simplest expectation was that the degree of overexpression of the unbalanced gene would be 
about 50% [Hattori et al. 2000] and it now seems to be generally true [Amano et al. 2004, Dauphinot et al. 
2005]. This raises the question of how such a relatively modest increase in gene expression can have such 
deleterious consequences. The genes in triplicate Hsa21 have an effect on the entire integrated genome 
and affect the expression of many other genes, activating or inhibiting, depending on the individual genetic 
constitution (genetic polymorphism): this could explain the variability of phenotypic expression and diversity 
disease in individual patients with DS. 
Finally trisomy for functional non-protein-coding DNA elements might be involved in some of the 
abnormal phenotypes. Comparative analysis of human with other vertebrate genomes revealed the 
presence of conserved regions that are not part of the annotated genes [Dermitzakis et al. 2005]. The 
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sequence conservation strongly indicates that these elements are functional, but the precise function of 
each one of them is unknown. It is however possible that three copies of some of the conserved elements 
contribute to the DS pathology. 
 
 
3. The Down Syndrome: pathogenic aspects 
Similar to almost all conditions that result from chromosome imbalance, DS affects multiple systems 
and produces both structural and functional defects [Epstein, 2001]. In addition, the evolution of the 
phenotype has a temporal dimension so the issues concerning affected individuals, their families and 
society change with age. A chronology of the major components of the DS phenotype is presented in Table 
1. 
 
 
Table 1: Major components of the phenotype of Down syndrome (Source: “The challenge of Down syndrome”, 
Antonarakis et al, 2006) 
 
The clinical diagnosis of DS can be made at birth on the basis of the presence of marked hypotonia 
and a constellation of minor dysmorphic features that involve all parts of the body but are especially visible 
in the craniofacies, hands and feet. Nevertheless, these dysmorphic features have little effect on function. 
Anyhow, there are two groups of major congenital abnormalities associated with DS, congenital heart 
disease and several types of gastrointestinal-tract obstruction or dysfunction, that can cause morbidity or 
even death if untreated. 
In recent years considerable progress has been made in understanding and explanation of the 
genetic mechanisms underlying the main phenotypic characteristics of DS: developmental abnormalities, 
susceptibility to certain diseases, disability. In particular, through an algorithm to identify non-coding RNAs, 
five microRNAs (miRNAs) have been identified on Hsa21 [Kuhn et al. 2008, Sethupathy et al. 2007]. Micro-
RNAs regulate the expression of other genes [Bartel, 2004], and their role in DS is not fully understood. 
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The five miRNAs are: miR-99a, let-7c, miR-125b-2, miR-155, and miR-802; the overexpression of these 
miRNAs, in the presence of trisomy 21, results in reduced expression of the encoded protein (down-
regulation effect), at fetal heart and nervous tissue, resulting in the heart and brain abnormalities 
characteristic of DS [Kuhn et al. 2008]. 
Moreover, a recent paper has suggested that trisomy of the Hsa21 genes, dualspecificity tyrosine-
(Y)-phosphorylation-regulated kinase 1A (DYRK1A) and regulator of calcineurin 1 (RCAN1), may have an 
impact on the development of multiple tissues [Arron at al. 2006]. DYRK1A is a priming kinase that 
facilitates the further phosphorylation of numerous proteins by other kinases (Figure 1) [de Graaf et al. 
2004 and 2006; Adayev et al. 2006; Kim et al. 2006; Ryoo  et al. 2007 and 2008; Huang et al. 2004; Woods 
et al. 2001; Aranda et al. 2008; Gwack et al. 2006] and that is up-regulated in a number of tissues from 
people with DS [Dowjat  et al. 2007; Liu et al. 2008]. RCAN1 is a regulator of the protein phosphatase 
calcineurin [Fuentes et al. 2000]. Crabtree and colleagues hypothesized that trisomy of these two genes 
may act synergistically to alter signalling via the NFAT family of transcription factors [Arron et al. 2008]. 
 
 
 
Figure 1: Dualspecificity tyrosine-(Y)-phosphorylation-regulated kinase 
1A (DYRK1A) (Source: “Down syndrome – recent progress and 
future prospects”, Wiseman et al. 2009) 
 
In an independent study, increased DYRK1A gene dosage decrease the expression level of RE1-
silencing transcription factor (REST) [Canzonetta et al. 2008], which is required both to maintain 
pluripotency and to facilitate neuronal differentiation; so a perturbation in REST expression may alter the 
development of many cell types. Indeed, over expression of DYRK1A in some animal models is associated 
with a number of phenotypes, including heart defects and abnormal learning and memory (Figure 2) [Arron 
et al. 2006; Ryoo et al. 2007; Altafaj et al. 2001; Martinez et al. 2004; Ahn et al. 2006]. However, not all 
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animal models that over-express DYRK1A exhibit these defects, suggesting that the outcome of DYRK1A 
trisomy could be affected by polymorphisms or differences in the expression of other genes [Olson et al. 
2004]. 
 
 
 
Figure 2: Main roles of DYRK1A in various cellular processes and their correlation 
with the neurodegenerative phenomena taking place in Down syndrome 
(Source: “Two key genes closely implicated with the neuropathological 
characteristics in Down syndrome: DYRK1A and RCAN1.”, Park et al. 
2009) 
 
 
3.1 Phenotypic variability 
Almost every aspect of the phenotype of DS is subject to a high degree of variability [Antonarakis 
and Epstein, 2006]. No two patients are likely to have exactly the same combination of features and none 
of the minor dysmorphic features is present in >80% of the cases. Nevertheless, even when superimposed 
upon familial features, the overall pattern of minor anomalies is consistent and distinct, and enables clinical 
recognition [Epstein, 2001]. 
Furthermore, life expectancy of DS individuals has been rapidly increasing over the past 20 years, 
with a doubling of the median age of death in white populations (up to 50 years in 1997), even if 
environmental effects that result from social disparities seem to have deprived various ethnic groups of 
similar benefits [Yang et al. 2002, Leonard et al. 2000]. 
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3.2 Congenital Heart Defects and Gastrointestinal System Malformations 
Approximately half of all children with DS are born with a signiﬁcant congenital heart defect (CHD), 
the most common of which is an atrioventricular septal defect (AVSD) [Freeman et al., 1998]. 
Typically developing children with CHD have been shown to have neurocognitive and psychomotor 
deﬁcits [Malec et al. 1999]. For instance, school-aged children with hypoplastic left heart syndrome have a 
mean full-scale IQ of 86, which is below the population normative value, approximately one standard 
deviation [Mahle et al. 2006]. Visootsak et al. (2011) have documented that there may be possible 
developmental differences in children with DS+AVSD compared to children with DS without CHDs. Issues 
that remain largely unknown in children with DS+AVSD are the magnitude of their cognitive, language, 
motor, social, and adaptive deﬁcits; the patient-related characteristics and perioperative factors may 
inﬂuence their neurodevelopmental outcomes and the effect of home environmental variables on their 
development. 
Gastrointestinal defects are second to heart defects among the common serious structural birth 
defects associated with DS [Fabia  and Drolette, 1970; Kallen et al. 1996] and atresia/stenosis of the small 
intestine were most common [Cleves et al. 2007]. 
 
3.3 Immune and Hematopoietic Systems 
In addition to the effects on function of the heart and gastrointestinal system, trisomy 21 also 
produces many changes in cellular function [Epstein, 2001]. Among these, those involving the immune and 
hematopoietic systems. The impact of infection has been greatly reduced with the availability of 
immunizations for various viral and bacterial pathogens, improved hygiene and antibiotics, however 
infection is still a major cause of death in DS at any age [Hill et al. 2003], and has been suggested that this 
susceptibility to infection depends on abnormal maturation of the thymus and impaired function of T 
lymphocytes [Philip et al. 1986, Murphy et al. 1995]. Franceschi et al. (1978) found a decreased 
percentage of T lymphocytes and an increased percentage of ―null cells‖ (non-T, non-B lymphocytes), so 
the immunologic defect seems to be a congenital feature of DS, and the antigen overloading could worsen 
the intrinsic immunological derangement and lead to a stress-immunodeficiency. In particular subjects with 
DS showed normal responsiveness in allogeneic mixed lymphocyte reactions, but their response to 
phytohemagglutinin and in autologous mixed lymphocyte reactions were severely impaired; moreover, the 
blood concentration of serum thymic factor in the majority of DS subjects was much lower than that found 
in age-matched healthy controls [Franceschi et al. 1981]. 
Furthermore, infants with DS develop acute leukemia, most commonly acute megakaryoblastic (M7) 
leukemia, with a frequency twenty times higher than that in the normal population [Hitzler et al. 2003]. This 
is often preceded by a neonatal leukemoid reaction (transient myeloproliferative disorder), which might be a 
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form of transient leukemia. A unique non-activating mutation in the GATA binding protein 1 (GATA1) gene 
(on the X chromosome) has been found in association with both the leukemia and the leukemic reaction 
[Hitzler et al. 2003, Wechsler et al. 2002], and children with DS seem to have a better prognosis and 
require less chemotherapy than children without DS [Gamis, 2005]. 
 
3.4 Central Nervous System 
The trisomic state hits the Central Nervous System (CNS), which results vulnerable throughout life. 
The brain is grossly normal with the exception of some degree of hypoplasia of the cerebellum [Aylward et 
al. 1997]. Nevertheless, perhaps the most frequent sign of DS is a central hypotonia, followed by delayed 
cognitive development in infancy and childhood leading to mild to moderate mental retardation, and a loss 
of cognitive abilities in adulthood and the development of Alzheimer‘s disease (AD) in later years [Busciglio 
et al. 2002]. 
The literature shows that the 8-13,6% of individuals with DS develop epilepsy, [Pueschel et al. 1991; 
Goldberg-Dtern et al. 2001], that cognitive development is in the range of mental retardation (usually grade 
medium-mild) [Brown et al. 1990] and that there is a frequency of autistic disorder, 7-11% [Kent et al. 1999; 
Kroeger and Nelson, 2006]. 
In general, the stages of development follow the normal sequence, with a particular deficit in the 
production of language [Chapman et al. 1998]; in childhood have been reported behavioral disorders such 
as attention deficit hyperactivity disorder (6.1% of cases), oppositional defiant disorder conduct (5.4%) or 
aggressive behavior (6.5%) while it can take as an adult major depression (6.1%) or aggressive behavior 
(6.1%) [Myers and Pueschel, 1991]. 
All domains of intellectual function do not have uniformly cognitive impairment, and there are both 
strengths and weaknesses in intellectual ability [Nadel 2003]. The forms of learning that depend on the 
hippocampus are particularly affected, and there is also evidence for impairment of prefrontal cortex and 
cerebellar functions [Nadel 2003]. Speech and articulation are particularly affected. Numerous anatomical, 
biochemical and physiological studies have shed little light on the basis for cognitive impairment [Epstein, 
2001]. Several years ago have been observed morphological abnormalities of the dendritic spines, which 
are the sites of synapse formation, and this originally non-specific finding has been considerable 
reappraised with the discovery of similar abnormalities in the brains of Ts65Dn mice [Belichenko et al. 
2004]. Hippocampal neurons in Ts65Dn brains also exhibit major abnormalities in long-term potentiation 
(LTP) and long-term depression (LTD), which are electrophysiological phenomena associated with learning 
and memory [Kleschevnikov et al. 2004]. The finding of similar abnormalities in the brains of people with 
DS might increase the understanding of the basis of cognitive impairment in DS and might provide potential 
therapeutic targets [Antonarakis and Epstein, 2006]. Moreover, another abnormality in the Ts65Dn mouse 
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brain might be directly relevant to humans, i.e. the progressive loss and atrophy of cholinergic neurons in 
the basal forebrain [Salehi et al. 2006; Granholm et al. 2000], a neuronal population that is particularly 
vulnerable in AD. 
The diagnosis of dementia in DS requires an understanding of baseline cognitive and emotional 
functioning in the disorder. For example, most healthy people with DS prior to the onset of dementia would 
score below detectable levels on the Mini Mental State Examination, a screening test for dementia 
administered to risk individuals in the general population. In the child and adult with DS, measures of IQ, 
general cognitive functioning, and mental age are at least two standard deviations below the norm and 
these global anchor measures appear to exceed performance in language, phonology, and memory [Miller, 
1988]. Auditory verbal memory is selectively impaired beyond global baseline functioning [Varnhagen et al., 
1987]. These findings can become confounding factors for the determination of dementia in DS and have 
led to a consensus statement for testing individuals at risk [Aylward et al., 1997]. One alternative to 
traditional direct testing of adults with developmental disabilities involves looking to sources other than the 
patient for information [Burt et al., 1998]. 
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Chapter 2 
 
DOWN SYNDROME AND ACCELERATED AGING 
 
 
1. Introduction 
In the previous chapter we described the cytogenetic and pathogenic aspects of DS in which multiple 
major aspects of the senescent phenotype appear. In other words, it has been shown that most features of 
physiological aging appear in DS earlier than in karyotypically normal age-matched subjects. 
During the last two generations there was a highly significant change in the survival of people with 
DS. In fact, while in the 1940s, the average life expectancy for individuals with DS was 12 years [Penrose, 
1949], individuals with DS now enjoy life expectancies into their 60s [Bittles and Glasson, 2004] thanks to 
medical breakthroughs and improvements in services. Along with this longer life expectancy comes a larger 
population of adults with DS who display premature age-related changes in their health status [Esbersen, 
2010]. Indeed, adults with DS experience much earlier than non trisomic people a series of age related 
phenomena such as Alzheimer-like dementia, altered free radical metabolism and impaired mitochondrial 
function that lead to neuronal degeneration [Lott et al. 2001; Busciglio et al. 2002 and 2007; Haan et al. 
2003], skin and hair changes, early onset menopause, visual and hearing impairments, adult onset seizure 
disorder, thyroid dysfunction, diabetes, obesity, sleep apnea and musculoskeletal problems [Esbensen, 
2010]. Therefore, DS has been often defined as an accelerated aging syndrome, even though aging is not 
so premature in DS as in other syndromes such as Hutchinson-Gilford progeria or Werner‘s Syndrome. A 
more detailed discussion on the main aspects of DS premature aging is reported below. 
 
1.1 Skin and Hair changes 
Adults with DS experience a number of dermatological and autoimmune symptoms characteristic of 
accelerated aging, such as hair loss, premature graying of the hair and wrinkling of the skin [Lott et al. 
1982]. Further, sun-exposure may have a greater effect on skin wrinkling for individuals with DS than for 
the general population, contributing to the appearance of premature skin aging in adults with DS [Brugge et 
al. 1993]. Significant differences in the skin and chronological age of the individual have been found in 
post-mortem examinations of the skin of adults with DS [Edwards, 1978]. 
Alopecia areata (the loss of hair) affects between 6% to 18.4% of adults with DS [duVivier & Munro, 
1975; Prasher, 1994b]. It is thought that this elevated rate of condition in adults with DS may be related to 
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immunological deficiency in thymus dependent function [Carter & Jegasothy, 1976]. Other skin conditions 
common in adults with DS include atopic dermatitis, fungal infections, seborrhoeic dermatitis, and xerosis, 
affecting 34% to 39% of adults [Kerins et al. 2008; Prasher, 1994b; Roizen & Patterson, 2003]. 
 
1.2  Vision and Hearing Impairments 
Visual impairments (44-71%) and eye abnormalities are common among aging adults with DS 
[Gardiner, 1967; Jacobson, 1988; McCarron et al. 2005]. Among visual impairments cataracts (11-33%), 
strabismus (23-37%), refraction problems (30-34%) and keratoconus (15%) are common ophthalmological 
problems [Aitchison, et al. 1990; Prasher, 1994b; Van Allen et al. 1999; Van Buggenhout et al., 1999). 
Age-related hearing loss is more common among adults with DS compared to the general 
population, and appears to have an earlier age of onset. High frequency sensorineural hearing impairments 
(such as presbycusis) in adults with DS onset about 20 to 30 years earlier than in their peers with 
intellectual disability (ID), and about 30 to 40 years earlier than in the general population [Buchanan, 1990]. 
Rates of hearing loss among adults with DS range from 12 to 72% [Howells, 1989; Prasher, 1994b; Van 
Buggenhout et al., 1999], and may depend on the nature of the hearing assessment. 
 
1.3 Seizure disorder 
Seizure increases with age for individuals with DS, especially for individuals suffering from comorbid 
dementia. One early estimate of the rate of seizures was 12.2% for adults with DS over the age of 55 and 
15.8% for adults over the age of 60 [Veall, 1974]. A lifespan study of individuals with DS found that 
approximately 8% of individuals with DS suffer from seizures, of which 40% experienced seizures after the 
age of 20 [Pueschel et al. 1991]. This higher rate of seizures may be related to the gene for myoclonus 
epilepsy being mapped to chromosome 21, even if this form of seizure is more commonly found in children 
and adolescents [Hattori et al. 2006]. In fact, older patients with DS typically have tonic-clonic, complex 
partial or simple partial seizures [Pueschel et al. 1991]. Alternatively, structural abnormalities and 
biochemical aberrations of the CNS in adults with DS may in part be responsible for increased seizure 
frequency [Pueschel et al. 1991]. 
 
1.4 Thyroid dysfunction 
The risk for thyroid disease increases with age in individuals with DS [Korsager et al. 1978). 
Approximately 35-40% of adults with DS have abnormal thyroid function, although only 7-8% have active 
hypothyroidism [Dinani & Carpenter, 1990; Prasher, 1994a; Prasher, 1994b]. Also comparable to seizure 
findings, the rate of thyroid disease in adults with DS is greater than that found in the general population 
[Coleman, 1994]. 
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1.5 Immune system changes 
In DS have been found clinical manifestations and biochemical markers indicative of the ―early 
aging‖, i.e. the production of autoantibodies and the development of autoimmune diseases. Kusters et al. 
(2009) hypothesized that the immune system in DS is intrinsically deficient from the very beginning, and not 
simply another victim of a generalized process of precocious aging. 
In DS patients are observed multiple immunological abnormalities, including alterations in 
subpopulations of lymphocytes, disorders of the cells of immune system, cancer cell growth and production 
of autoantibodies; they are more frequently age-related abnormalities and part of the ―early aging‖ 
framework [Cossarizza et al. 1990]. Another characteristic of DS subjects is represented by the progressive 
expansion of the non-functional natural killer, resulting in a deficiency of natural killer activity itself 
[Cossarizza et al. 1991]. 
 
1.6 CNS changes 
In DS subjects, the deposition of amyloid protein is first observed in the second decade of life 
[Rumble et al. 1989], and the full pathology of AD seems to be invariably present from 35 years of age 
onwards – thirty to forty years earlier than in the normal population. Nevertheless, the age-associated 
decrease in cognitive function observed in DS subjects is still a matter of study, as its features and 
molecular mechanisms are largely not elucidated. 
Patients with AD in the general population and DS were been evaluated by informant measures of 
language and emotional functioning [Nelson et al., 1995]. The early presentation of dementia in DS seems 
to be characterized by depression, indifference, and pragnosia (socially deficient communication). These 
variables reflect emotional change and pragmatic language functioning and they correlate highly with the 
presence of pathological release reflexes on the neurological examination and the presence of cortical 
atrophy on the MRI scans of demented patients with DS. Taken together, these factors may be considered 
a sign of prefrontal lobe dysfunction in DS that causes inattentiveness, heightened threshold to stimulation,  
apathy, decomposition of gait, labile mood and sphincteric incontinence. 
 
 
 
 
 
 
 
18 
 
2. Alzheimer’s disease in Down Syndrome 
The ability to detect dementia in DS population is hampered by developmental differences as well as 
the sensitivity of existing test tools. Despite the apparent clinical heterogeneity in aged individuals with DS, 
age-associated neuropathology is a consistent feature [Lott and Head, 2001]. 
The first description of the link between DS and AD is found in an English publication by Jervis 
(1948) who described three individuals with DS (>40 years) who had intellectual deterioration, neuronal 
cells loss, senile plaques and neurofibrillary tangles. Neuropathological evidence of the association 
between DS and AD was described by many scientists [Struwe, 1929; Bertrand and Koffas, 1949]. In the 
subsequent three decades numerous reports have shown that the brain lesions of AD in DS, visualized by 
light and electron microscopy, were similar, if not identical, to the findings of AD in the general population 
[Lott, 1982, 1986 and 1992]. In 1972, Malamud published a monograph characterizing the age-dependency 
of AD in DS and reported that the microscopic characteristics of AD were ubiquitous in brain samples of 
individuals with DS over age 40 years. 
 
 
2.1 APP gene 
The two neuropathological features necessary for a diagnosis of AD are neurofibrillary tangles and 
senile plaques [Kachaturian et al., 1985; Mirra et al., 1991; National Institute on Aging, 1997], of which the 
principal component is β-amyloid (Aβ), a hydrophobic 39 to 43 amino-acid peptide which can adopt a β-
pleated sheet configuration. Aβ is derived from the proteolytic processing of a longer amyloid precursor 
protein (APP), a member of a large family of 70-kDa transmembrane glycoproteins derived from alternative 
splicing of precursor mRNA [Selkoe, 1996]. APP gene is located on chromosome 21 (21q21) so, in DS, it is 
over-expressed and triplicated in virtually all forms of the disorder [Tanzi et al., 1987; Kang et al., 1987]. 
This over-expression of APP probably accounts for the early deposition of Aβ in the brains of children with 
DS as early as eight years [Leverenz and Raskind, 1998]. By age of thirty years, Lemere et al. (1996) 
found Aβ deposition in up to fifty percent of brain from individuals with DS. Therefore Aβ accumulation 
appears to occur in an age dependent manner in DS and the syndrome could be a valuable model system 
for understanding senile plaque progression. 
Aβ is a long-lived peptide in which aspartic acid and asparagine at positions 1, 7, 23, and 27 are 
susceptible to chemical damage by nonenzymatic processes such as racemization, isomerization, and 
deamidation. The spontaneous post-translational modifications of these amino acids affect critical cellular 
and molecular events during aging by interfering with protein function.  
Several studies report the presence of spontaneously modified, and thus older plaque deposits in AD 
and DS brain [Fonseca et al., 1999; Azizeh et al., 2000]. The authors observed the distribution of longed 
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lived senile plaques in DS brain, using affinity-purified polyclonal antibodies for post translationally modified 
Aβ (with either a racemized or isomerized aspartic acid at position 7). The immuno-positive plaques were 
initially found in clusters within the superficial layers of the frontal and entorhinal cortex but, with advancing 
age, increasing numbers appeared in deeper layers. These findings suggest that there is a progression of 
Aβ deposition from superficial to deeper cortical layers. Previous reports of senile plaque pathogenesis in 
the brains of individuals with DS demonstrate that Aβ initially appears as clusters within supragranular 
cortical regions [Armstrong and Smith, 1994; Hof et al., 1995]. Moreover, the findings suggest that the 
earliest deposition of Aβ may involve the frontal cortex which, in turn, may account for the frontal lobe 
symptomatology which characterizes the earliest stages of dementia in DS. 
Once initial Aβ or neurofibrillary tangle pathology has appeared in the DS brain, Aβ deposits, 
neurofibrillary tangles, and cognitive decline in individuals with DS after age 35–40 years increase 
exponentially [Coyle et al., 1986; Mann et al., 1988; 1989; Mann et al., 1992; Wisniewski and Wegiel, 1992; 
Armstrong et al., 1994; Hof et al., 1995; Hyman et al., 1995; Leverenz et al., 1998]. Prevalence studies of 
dementia in DS have shown a clinical correlation of the neuropathological changes and only eight percent 
of individuals between 35–49 years showed cognitive decline with the prevalence rising to over seventy-
five percent above age sixty years [Lai and Williams, 1989]. Thus, although the deposition of amyloid 
appears to be linear throughout the lifespan in DS, additional factors seem to be involved in the marked 
increase in both neuropathology and clinical dementia in the fourth and fifth decades. 
Inflammatory factors may also play a significant role in the development or acceleration of AD 
pathology in DS. For example, the levels of interleukin-1, a proinflammatory cytokine, and S100β increase 
in the brain [Griffin et al., 1989]. Activation of the proinflammatory classical complement cascade in 
association with the development of amyloid pathology contribute to strengthen the role of inflammatory 
processes possibly accelerating DS pathology [Lott and Head, 2001]. 
 
2.2 APOE gene 
In a meta-analysis, Deb et al. (2000) concluded that demented adults with DS showed a significantly 
higher frequency of ε4 allele of the apo-lipoprotein gene compared to nondemented adults. 
Apolipoprotein E (APOE) is a polymorphic protein encoded by a gene located on human 
chromosome 19q13.2; it has a central role in plasma lipoprotein metabolism and cholesterol homeostasis 
for its ability to interact with the LDL receptor and the LDL receptor-related protein; APOE is the major 
apolipoprotein in brain, its production and accumulation are increased in CNS disorders and in peripheral 
nerve injury [Weisgraber et al. 1994]. 
There are three common alleles of the APOE gene, indicates as APOE ε2, ε3, ε4. Numerous report 
have established that the frequency of the ε4 allele increases in late-onset familial and in sporadic AD 
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[Corder et al. 1993; Tsai et al. 1994; Saunders et al. 1993]; yet, APOE ε4 allele must not be considered as 
a genetic mutation causing AD, but rather as a susceptibility gene or risk factor for earlier onset. In fact, 
reactions of immunoreactivity has been shown APOE within senile plaques [Schmechel et al. 1993], 
suggesting the possible role of APOE as a pathological ―chaperon protein‖ involved in insoluble amyloid 
formation. It has been also demonstrated that the development of pathologic changes in DS cases does 
not always parallel that observed in AD patients; in particular amyloid accumulation represents a major and 
early feature of DS but it is not considered a critical factor in the development of the dementia that occurs in 
most DS patients only after 50 years [Wisniewski et al. 1995]. 
Del Bo et al. (1997) have observed that DS patients do not differ from the general population in 
terms of the ε4 allele‘s frequency; in agreement with this evidence, no significant differences in ε4 allele 
frequency between AD-DS cases and DS controls have been detected [Van Gool et al. 1995]. 
A previous report on DS patients described an association between longevity and the absence of 
clinical evidence of dementia [Royston et al. 1994], suggesting a modulation of the clinical phenotype of DS 
by genes on chromosomes other than chromosome 21. 
How APOE4 protein can contribute to quicken the progression of mental retardation is unknown, but 
it is important to underline that a single amino acid difference between APOE3 and APOE4 isoforms is able 
to produce a remarkable biological effect on the expression of mental decline. Specifically, data presented 
by Del Bo et al. (1997) show a significant inverse correlation between full scale IQ values and age in the 
subgroup of DS patients having at least one APOE ε4 allele. 
Anomalies of the developmental processes and metabolic alterations due to partial or total gene 
dosage of chromosome 21 may affect cortical neuronal function in DS subjects. In particular, the triplication 
of chromosome 21 could induce the overexpression of other proteins other than β-amyloid, such as CuZn-
superoxide dismutase, S100 β protein and the glutamate receptor subunit GluR5, which might participate 
actively in the accelerated degenerative process observed in DS patients [Dickinson and Singh, 1993; 
Becker et al. 1993]. 
 
2.3 Oxidative stress 
Individuals with DS share a common predisposition towards oxidative stress (OS). Oxidative stress 
results from an imbalance in the metabolism of free radicals such as reactive oxygen species (ROS) and it 
is thought to have a direct role in the development of neuropathological changes of AD in DS [Kedziora and 
Bartosz, 1988; Busciglio et al., 1998]. 
The most susceptible target of ROS are mitochondria and mitochondrial control region mutations 
occur both in demented individuals with DS and in those with AD in the general population [Coskun et al. 
2010]. Mitochondrial membrane potentials measured in blood mononuclear cells from individuals with DS 
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are more susceptible to damaging agents than controls [Roat et al. 2007]. Oxidative stress is significant 
even in fetuses with DS, as suggested by functional genomic analysis of amniotic fluid cell-free mRNA 
[Slonim et al. 2009]. While oxidative stress and antioxidant systems are involved in the cognitive 
dysfunction associated with the pre-demented state in DS, the relationship to genes and gene products is 
not yet clear [Strydom et al. 2009]. Oxidative stress seems to start before birth because the glycation end 
products, associated with cellular oxidation, increased in brains from fetuses with DS [Odetti et al. 1998]. 
Oxidative stress is also increased in mouse models for DS. In mouse the trisomy 16, which has 
genetic homology to human chromosome 21, is associated to decreased respiration at the level of 
Complex I in mitochondria [Bambrick and Fiskum, 2008] and to increased of lipid peroxidation, a measure 
of oxidative stress, in the brain [Ishihara et al., 2010]. In this model oxidative stress has been identified 
even as a possible therapeutic target [Gardiner, 2010]. In fact, alpha-tocopherol, an antioxidant, delayed 
the onset of cognitive and morphological abnormalities in the Ts65Dn mouse [Lockrow et al., 2009] and 
reduced the oxidation state of S100β protein and subsequently its influence on the neuroinflammatory 
process [Bialowas-McGoey et al., 2008]. 
However, not all investigators agree on the importance of oxidative stress factors in DS. For 
example, Hayn et al. (1996) found no abnormalities in brain concentration of SOD-1, glutathione 
peroxidase, malondiadehyde, or o-tyrosine in DS compared to controls, although the level of choline 
acetyltransferase was reduced (in keeping with the cholinergic deficit). Likewise there appears to be 
evidence against a damage to nuclear DNA isolated from cortical brain areas in DS and induced by the 
increased ROS [Seidl et al., 1997]. 
Head et al. (2000) suggest that oxidation of Aβ is an early event in neuritic plaque biogenesis. The 
distribution of oxidatively modified Aβ in the entorhinal and frontal cortex in DS, AD, and canine brain, 
oxidized Aβ was observed within a subset of diffuse plaques and the cores of neuritic plaques. Confocal 
studies indicated that oxidized Aβ deposits were within activated microglia, suggesting that this oxidative 
modification may seed the formation of neuritic and cored plaques. Oxidative modifications of amyloid lead 
to more highly aggregated and insoluble deposits suggesting that this is a potential mechanism by which 
amyloid pathology is initiated and propagated in DS with AD. 
These studies suggest that oxidative damage and amyloid accumulation interact and thus 
administration of an antioxidant on a chronic basis may delay the start of dementia in DS or slow its course 
[Lott and Head, 2001]. 
Figure 1 summarizes the relationship between oxidative stress, Aβ deposition, and 
neurodegeneration in AD. It is supposed that oxidative stress may exacerbate Aβ aggregation [Dyrks et al. 
1992], while fibrillar Aβ may increase intraneuronal generation of free radicals [Behl et al. 1994] and trigger 
an inflammatory reaction causing further oxidative damage [Pachter, 1997]. 
22 
 
 
Figure 1: Mechanisms of neuronal death in Alzheimer’s disease (Source: “Stress, Aging, and 
Neurodegenerative Disorders”, Busciglio et al. 1998) 
 
Aging, DS or gene mutations associated with familial AD might be considered predisposing factors 
which contribute by either increasing oxidative stress [Carney J and Carney A, 1994] or Aβ production and 
deposition [Selkoe, 1997], and impair mitochondrial function, resulting in energy depletion followed by 
further neuronal degeneration [Flint Beal, 1992]. Finally, impaired cellular energy metabolism increases the 
amyloidogenic processing of the Aβ precursor protein [Gabuzda et al. 1994] potentially leading to increased 
Aβ production. In this context, neuronal death would be caused by the simultaneous action of oxidative 
stress, Aβ cytotoxicity and excitatory amino acids cytotoxicity. 
Combined therapeutic intervention to prevent the neurodegenerative process can involve antioxidant 
strategies, treatments designed to inhibit Aβ deposition and/or fibrillization, protection of mitochondrial 
function and energy production, and prevention of the inflammatory and excitotoxic processes [Busciglio et 
al. 1998]. 
2.4 The “gene-dosage” and the “two-hit” hypothesis 
The “gene dosage effect” hypothesis holds that the dosage imbalance of a specific individual gene 
or a small group of genes is responsible for the specific individual DS traits [Korenberg et al. 1990; Reeves 
et al. 2001]. Overexpression of the encoded proteins by Chr 21 leads to overconsumption of their 
substrates and overproduction of their metabolic end-products. The best-documented gene products of this 
phenomenon are the amyloid precursor protein (APP) and the cytoplasmic enzyme Cu2+/Zn2+ superoxide 
dismutase (SOD-1) (Figure 2), both of which are responsible for the regulation of reactive oxygen species 
(ROS) homeostasis [Schuchmann and Heinemann, 2000], which may be a fundamental factor in the 
development of oxidative stress (OS), preceding the signature pathology by decades and leading to 
neuronal death and disease progression. Additionally, on the long arm of Chr 21 (21q) there is the DS 
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critical/candidate region (DSCR) (q22.3), which includes the gene of cystathionin β-synthase (CBS), the 
gene for the S100β calcium-binding protein and that for the β -site APP-cleaving 2 enzyme (BACE2) 
(Figure 2). Another gene contained by 21q is the gene coding for the trifunctional enzyme complex 
glycinamide ribonucleotide synthase–aminoimidazole ribonucleotide synthase–glycinamide formyl 
transferase (GARS–AIRS–GART) (q22.1) (Figure 2), which catalyzes certain steps of de novo purine 
synthesis [Capone, 2000]. However, not all proteins whose genes are encoded on this chromosome 
display overexpression, suggesting that the DS phenotype cannot be explained simply by the ―gene 
dosage effect‖ [Cheon, 2003]. 
 
Figure 2: Chromosome 21: localization of the most important AD and DS related genes (Source: “Oxidative 
stress: A bridge between Down’s syndrome and Alzheimer’s disease”, Zana et al. 2007) 
 
The “two-hit” hypothesis for AD has been recently proposed. Initiating event can independently be 
either OS or alterations in mitotic signaling, but both processes are necessary and sufficient to propagate 
AD pathogenesis [Zhu et al. 2004]. According to this model, the first insult may leave neurons very 
vulnerable to an additional insult. In particular, it has been suggested that susceptible neurons (under 
stress or bearing mutations) devote their compensatory potential to adjusting to current stimuli and thereby 
lose the capability of further adaptation needed to respond to other insults in the future. Therefore it seems 
to be that the OS alone is a necessary, but not sufficient, event leading to AD [Zana et al. 2007]. 
 
 
3. Theories on aging 
Several theories have been proposed to account for the premature aging observed in adults with DS. 
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In recent decades, the study of aging has expanded rapidly. A number of theories (Table 1) have 
been generated by biological, epidemiologic and demographic data, in order to identify a cause or process 
to explain aging and its inevitable consequence, death [Weinert and Timiras, 2003]. However, in recent 
years, the view of aging as an extremely complex, multifactorial process has replaced the search for a 
single cause of aging, such as a single gene or the decline of a key body system [Kowald and Kirkwood, 
1996]. Several processes may interact simultaneously and may operate at many levels of functional 
organization [Franceschi et al, 2000a]. Similarly, different theories of aging are not mutually exclusive and 
may adequately describe some or all features of the normal aging process alone or in combination with 
other theories. 
 
 
Table 1: Classification of the most important theories of aging (Source: “Invited Review: Theories of aging”, Weinert 
and Timiras, 2003) 
 
3.1 The evolutionary theories 
Evolutionary theories argue that aging results from a decline in the force of natural selection. Since 
evolution acts primarily to maximize reproductive fitness in an individual, longevity is a trait to be selected 
only if it is beneficial for fitness. Life span is, therefore, the result of selective pressures and may have a 
large degree of plasticity within an individual species, as well as among species. The evolutionary theory 
was first formulated in the 1940s based on the observation that Huntington‘s disease, a dominant lethal 
mutation, remained in the population even though it should be strongly selected against [Haldane, 1941]. 
This observation inspired the Mutation Accumulation Theory of aging, which suggests that detrimental, 
late-acting mutations may accumulate in the population and ultimately lead to pathology and senescence 
[Medawar, 1952]. Life span is largely a function of survivability and reproductive strategy in a competitive 
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environment, so it is species-specific. Consequently, organisms that die primarily from predation and 
environmental hazards will evolve a life span optimized for their own particular environment. The 
observation that organisms can age in a natural environment [Loison et al. 1999] indicates that extending 
life span can be beneficial to fitness, but there are other considerations that might necessitate sacrificing 
longevity for reproductive fitness. This concept is the basic idea of the Disposable Soma Theory of aging 
which argues that the somatic organism is effectively maintained only for reproductive success; afterward it 
is disposable. In other words, somatic maintenance, in particular, longevity, has a cost; the balance of 
resources invested in longevity vs. reproductive fitness determines the life span. 
The concept of an evolutionary tradeoff is also essential in the Antagonistic Pleiotropy Theory, in 
addition to the Disposable Soma Theory. The first suggests that some genes may be selected for beneficial 
effects early in life and yet have unselected deleterious effects with age, thereby contributing directly to 
senescence; the second explains why we live for a certain period of time but does not postulate the specific 
cause of aging. 
 
3.2 The Network Theory 
In 1989 Franceschi proposed that aging was directly controlled by a network of cellular and 
molecular defence mechanisms, so called the Network Theory of aging [Franceschi, 1989]. The aim of this 
theory was to combine suggestions deriving from evolutionary theories of aging [Kirkwood, 1977; Kirkwood 
and Holliday, 1979] with data emerging from cellular and molecular biology of aging. Indeed, cells are 
constantly exposed to a variety of internal and external stressors, which are potentially dangerous for the 
maintenance of cell functional integrity. Such stressors are very diverse and include different physical (UV 
and gamma radiation, heat), chemical (components of the body and products of metabolism, such as 
oxygen free radicals and reducing sugars), and biological agents (viruses). In the course of evolution, 
however, a number of mechanisms have emerged, such as DNA repair systems, production of heat shock 
proteins (HSP), antioxidant defense systems either enzymatic or non-enzymatic, activation of poly (ADP-
ribose) polymerase (PARP), allowing the cell to overcome these potentially harmful agents (Figure 3). 
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Figure 3: The “anti-aging” cellular defense network (Source: 
“Inflamm-aging. An evolutionary perspective on 
immunosenescence”, Franceschi et al, 2000b) 
 
A failure of these mechanisms does not allow the cell to maintain its homeostasis and this fact 
coincides with cell senescence (aging at the cellular level). However, the persistence of factors involved in 
these defense mechanisms, such as Hsp70 and catecholamines, is highly toxic, so the strategy is to 
maintain long-term survival stress responses in a fixed range, beyond which the ability to survival decades 
because of insufficient responses or, conversely, because of excessive responses [Franceschi et al, 
2000a]. 
 
3.3 The Remodeling Theory 
Over the years has become increasingly important the question of what was the contribution of the 
immune system to longevity [Franceschi et al, 1995; Franceschi and Cossarizza, 1995]. From this need 
was born the idea of studying healthy centenarians as a model of physiological aging and 
immunosenescence. 
The Immunosenescence is the net result of continuous adaptation to changes in the body that are 
deteriorating over time. The body‘s resources are continuously optimized, and immunosenescence is a 
dynamic process, which includes a loss that is a purchase. Centenarians in good health are considered as 
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the model for excellence for the study of aging as they have the best ability to adapt to damaging agents 
and particularly harmful to stress [Franceschi et al, 1995]. 
One of the main feature of the aging process appears to be a progressive pro-inflammatory state 
given by continuous antigenic challenge, resulting by chronic exposure to antigens. This process has been 
defined Inflammaging [Franceschi et al, 2000b] and is characterized by a dichotomy in which the 
evolutionary innate immunity is largely preserved or even activated and provides a background for the 
biological susceptibility to age-related diseases. In particular, the beneficial effects of inflammation, aimed 
at the neutralization of harmful agents at early and adult life, may become detrimental in later life. 
Moreover, the absence of robust (protective and predisposing) gene variants and/or the presence of weak 
(or frail) genetic variants are probably necessary to develop age-related diseases and organ-specific with 
an inflammatory pathogenesis, such as atherosclerosis, Alzheimer‘s disease, osteoporosis, and diabetes. 
Thus a model for the genetic basis of inflammaging can be proposed, in which apolipoprotein E is assumed 
to represent a prototypical frailty gene and IL-6/IL-10 to represent prototypical pro-inflammatory and anti-
inflammatory genes (Figure 4). According to this model, the individual‘s genetic make-up is responsible for 
different trends of the age-related increase in inflammaging (the slope of inflammaging) [Franceschi and 
Bonafè, 2003]. 
 
 
Figure 4: (Source: “Centenarians as a model of healthy aging”, Franceschi and Bonafè, 2003) 
 
Thus, inflammaging could be the ultimate proof that the beneficial effect of the defense system 
network (innate immunity, stress, and inflammation), devoted to the neutralization of dangerous/harmful 
agents early in life and in adulthood, turns out to be detrimental late in life, in a period largely not foreseen 
by evolution. Thus, a tradeoff between early beneficial effects and late negative outcomes can occur at the 
genetic and molecular level. Similar phenomena have been predicted by evolutionary geneticists who 
proposed the theory of antagonistic pleiotropy [Franceschi et al, 2000b]. 
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3.4 mtDNA damage and the mitochondrial theory of aging 
Among all aging theories, the Freee Radical Theory is one of the most gained and discussed 
(Figure 5). 
 
Figure 5: (Source: “An update of the oxygen stress-mitochondrial mutation 
theory of aging: genetic and evolutionary implications”, Miquel J, 1998) 
 
It has been proposed for the first time by Harman in 1957 and explains how aging is strictly 
associated with high level of free radicals, chemical species with a free electron in their external orbital and, 
for this reason, they are extremely reactive and instable. An increasing speed of producing reactive oxygen 
species (ROS), a decline of antioxidant defense system and a low efficiency in repairing damaged 
molecules are conditions related to oxidative stress, which could interact with aging. 
Although the available evidence strongly suggests that mitochondria play a role in this process, there 
appears to be a wide range of opinions as to the exact nature of the involvement of mitochondria in aging. 
The Mitochondrial Theory, proposed by Miquel in 1980, is considered an extension of the free radical 
theory. As it is commonly known, nDNA is protected by histone proteins and various repair enzymes, which 
minimizes damage to nDNA from free radicals/oxidants. mtDNA is organized into complexes called 
nucleoids, composed of proteins belonging to the mtDNA replisome that provide protection from oxidative 
stress and repair of damages [Chen and Butow, 2005]; nevertheless, the proximity to the main source of 
ROS, i.e. the electron transport chain (ETC), leads to a dramatically higher rate of damage with respect to 
nDNA. The commonest form of free radical damage to mtDNA molecules is the production of 8-OHdG, an 
oxidized guanine base. Even in young (3 month old) rats, the level of 8-OHdG is already 16 times higher in 
mtDNA than nDNA [Richter et al. 1995]. Since mtDNA damage accumulates during the life of an individual, 
the functionality of the ETC enzyme complexes that produce ATP and that are in part encoded by mtDNA, 
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decrease dramatically and gradually produces a cellular energy crisis. The system is not capable to keep 
the equilibrium and it leads to cellular aging and afterward to organism aging. The dramatic mutation rate 
causes defective structures formation in the respiratory chain and consequently a defective functionality 
which creates a rising in ROS production. This process is the so-called vicious cycle, which is the basis of 
the mitochondrial theory of aging, and in which somatic mutations of mtDNA engender respiratory chain 
dysfunction, enhancing the production of DNA-damaging oxygen radicals. 
When a new mtDNA mutation arises in a cell, a mixed intracellular population of mtDNAs is 
generated (wild-type and mutated mtDNAs), a state known as eteroplasmy. The mutant and normal 
molecules are randomly distributed into the daughter cells and as a consequence of this replicative 
segregation, the proportion of mutant and normal mtDNAs can drift toward an homoplasmic condition (all 
mutant or all wild type). 
Furthermore, it has been observed that in order to compensate the energy deficiency, mtDNA copy 
number is preferentially, clonally, amplified within cells with defective mitochondria [Coskun et al. 2003]. 
This may be a consequence of the nucleus attempting to compensate for the energy deficiency by 
providing the cell with more mitochondria and more mtDNA. As mutant mtDNA can have a replicative 
advantage, cells can be enriched in mutant mtDNA by genetic drift. As the percentage of mutant mtDNAs 
increases, the mitochondrial energetic output declines, ROS production increases, and the propensity for 
apoptosis increases. As cells are progressively lost through apoptosis, tissue function declines, ultimately 
leading to aging of the organism. Thus according to this theory the accumulation of mutant mtDNA creates 
the aging clock (Figure 6). 
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Figure 6: Aging model. The dot line shows the minimum number of cells for the tissue to function 
normally. In black are die cells in a mitochondrial-mediate process. In green cells with 
optimal function. (Source: “A mitochondrial paradigm of metabolic and degenerative 
diseases, aging, and cancer: a dawn for evolutionary medicine”, Wallace DC, 2005). 
 
 
3.5 Mitochondrial dysfunction and DS 
Probably the most accredited theory to explain premature aging in DS subjects is the Mitochondrial 
Dysfunction. Oxidative stress in DS has been documented in convincing epidemiological, in vitro and in 
vivo, data. For example, the level of malondialdehyde (MDA), a biomarker of lipid peroxidation, is elevated 
by 30–60% in the brain, erythrocytes, fibroblasts and urine and the level of 8-hydroxy-20-deoxyguanosine, 
a biomarker of oxidative damage to DNA, is increased by 70% [Anneren and Epstein 1987; Brooksbank 
and Balazs, 1984; Bras et al. 1989; Jovanovic et al. 1998; Busciglio and Yankner, 1995]. The mitochondrial 
respiratory system is the most important intracellular source of ROS and free radicals, and mitochondria 
have a central role in different types of apoptosis. Numerous studies have demonstrated that the 
accumulation of mitochondrial DNA (mtDNA) mutations is a major contributor to degenerative diseases and 
human aging.  
Busciglio and co-workers have shown that the level of intracellular ROS is increased 3- to 4-fold in 
DS neurons, with substantially elevated levels of lipid peroxidation that precede neuronal death [Busciglio 
and Yankner, 1995]. The source of these ROS is unknown, but it was shown that free radical scavengers 
were able to protect the neurons from cell death. The group also showed that in DS astrocytes there is a 
defect in AβPP processing that might either be the cause or effect of the observed mitochondrial 
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dysfunction. However, inhibition of mitochondrial function in normal cells induced similar abnormalities of 
AβPP processing, implying that mitochondrial dysfunction in DS cells is a cause of the AβPP processing 
defect. 
Arbuzova (1996 and 1998) has suggested that mtDNA mutations have a role in the pathogenesis of 
DS. Apart from helping to explain free radical damage and development of AD, the presence of mtDNA 
mutations could explain the association of DS with premature aging and diabetes, which can result from 
mtDNA mutations [Wallace, 1999]. Furthermore mtDNA is almost entirely of maternal origin, as is the extra 
chromosome 21 in the majority of DS cases, and examination of pedigrees from families with aneuploidy 
recurrence indicates cytoplasmic inheritance of a risk factor [Arbuzova et al. 2001].  
Mutations in mtDNA may cause an increase in the generation of free-radicals and reduce ATP 
levels. This, in turn, could affect the synaptonemal complex, chromosome segregation and division spindle, 
and could alter recombination, because the enzymes participating in recombination and DNA repair are 
ATP-dependent [Strick et al. 2000; Schar et al. 1997], leading to aneuploidy. Animal studies support the 
notion of the influence of mtDNA mutations on the meiotic apparatus. For example, the Dip 1 mutation in 
mice, which produces a high incidence of ovulated diploid oocytes, is carried by the mitochondria [Beerman 
et al. 1988]. It is notable that an impairment of the function of the oxidant–antioxidant system has been 
found in DS mothers and mtDNA sequencing in a donor of the extra chromosome 21 has identified a 
number of novel mutations all causing amino acid changes [Arbuzova, 1998]. 
Theoretically, both point mutations and micro-deletions could induce chromosomal non-disjunction. 
Arbuzova et al. (2002) have speculated that, rather than a single base change being responsible, several 
deleterious mutations decrease mitochondrial function in a different way but enough powerful to affect 
meiosis. 
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Chapter 3 
 
MITOCHONDRIAL GENETICS 
 
 
1. Introduction 
It has been suggested that the risk of Down syndrome is closely linked to maternal age. In the past 
the association of Down syndrome with age was explained by relaxation of selection against trisomic 
fetuses in older women, but recently there have been suggestions that it is due to meiotic error caused by 
the aging of oocytes [Ghosh et al. 2009]. However, the exact mechanism has not yet been determined. 
Mitochondria play an important role in meiosis of mammalian oocytes. In an experiment with mouse 
oocytes, it has been shown that mitochondria translocate to the perinuclear region during formation of the 
first metaphase spindle and disperse subsequently during the release of the first polar body. These 
rearrangements of mitochondria are regarded as essential for the specification of localized activities of ATP 
at the meiotic spindle and in order to facilitate development, a large supply of ATP is required [Van Blerkom 
et al. 1984, 1995, 1997, 1998]. According to Van Blerkom et al. (1998), mitochondrial dysfunction is due to 
a variety of intrinsic and extrinsic influences and it can profoundly influence the level of ATP generation in 
oocytes and early embryos; this in turn may result in aberrant chromosomal segregation or developmental 
arrest [Hsieh et al. 2001]. Chromosomal movements during meiosis are directed by microtubule assembly 
within the spindle. According to Battaglia et al. (1996), the spindle exhibited abnormal tubulin placement 
and one or more chromosomes were displaced from the metaphase plate during the second meiotic 
division in 79% of oocytes in an older age group under investigation. In contrast, only 17% of the oocytes 
from a younger age group exhibited aneuploidy. This indicates that regulatory mechanisms responsible for 
the assembly of the meiotic spindle are significantly altered in older women, leading to a higher prevalence 
of aneuploidy [Battaglia et al. 1996]. By inhibiting mitochondrial function in mice with chloramphenicol, 
Beermann and Hansmann (1986) demonstrated that defective mitochondrial function interferes with 
ordered chromosome segregation during the first meiotic division [Beerman et al. 1986 and 1988]. 
Mitochondrial dysfunction leads to oxidative damage and apoptosis, hypoxia, and deletion or point 
mutations in the mitochondrial genome; especially in oocytes of older women, these adverse influences 
may contribute to reduced mitochondrial function in the human female gamete. Linnane et al. (1989) 
speculated that the accumulation of mitochondrial DNA (mtDNA) mutations in oocytes result in a reduction 
of gene expression and since mtDNA can only be inherited through the maternal line, mitochondrial gene 
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expression measured in amniocytes, a fetal tissue, might reflect mitochondrial gene expression during 
meiotic division in oocytes, causing organ dysfunction. 
 
As we seen so far, mitochondria are organelles very important for the cells. They are considered the 
―cellular power plants‖, because in them occur the biochemical processes, the most important of which is 
oxidative phosphorylation (OXPHOS), that provide the energy to the cells they need for all their vital 
functions. Therefore, as already explained in the previous chapter, mitochondria and mtDNA might be 
heavily involved in aging, but mtDNA is characterized, as well as somatic mutations, by a peculiar genetic, 
which will be descrided later. 
 
 
2. Mitochondrial DNA 
Human mtDNA is a circular double-stranded molecule that is 16569 bp long (Figure 1). 
 
 
Figure 1: (Source: “Mitochondrial DNA and aging”, Alexeyev et al. 2004) 
 
It encodes 2 rRNAs, 22 tRNAs and 13 polypeptides, of which seven are components of complex I 
(NADH dehydrogenase), three are components of complex IV (cytochrome c oxidase), two are subunits of 
complex V (ATP synthase) and cytochrome b (a subunit of complex III) [Anderson et al. 1981]. The 
inheritance of mtDNA is exclusively maternal and mtDNA is present in one to several thousand copies per 
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cell [Takamatsu et al. 2002] and is ―encapsulated‖ into mitochondria at 1–11 copies per mitochondrion with 
the mean being two genomes per organelle [Cavelier et al. 2000]. The two mtDNA strands can be 
separated by denaturing caesium chloride gradient centrifugation [Kasamatsu and Vinograd, 1974]. In the 
heavy strand (purine-rich) is encoded most of the information, i.e. two rRNAs, 14 tRNAs and 12 
polypeptides. The light strand (pyrimidine-rich) contains genetic information for only one polypeptide and 
eight tRNAs. Mitochondrial genes have no introns, some of which overlap and, in some instances, 
termination codons are not encoded, but are generated post-transcriptionally by polyadenylation [Ojala et 
al. 1981]. Intergenic sequences are absent or limited to a few bases. MtDNA maintenance and transcription 
is totally dependent by nuclear-encoded proteins. In fact, the mitochondrial proteome consists of an 
estimate of 1500 polypeptides [Taylor et al. 2003] of which only 13 are encoded by its own DNA (Figure 2). 
 
 
Figure 2: Mitochondrial respiratory chain (Source: “Mitochondria: from bioenergetics to 
the metabolic regulation of carcinogenesis”, Bellance et al. 2009) 
 
MtDNA replication is conducted by the heterodimeric DNA polymerase γ [Lim et al. 1999]. 
Replication occurs bidirectionally, initiated at two spatially and temporally distinct origins of replication, OH 
and OL, for the heavy and light strand origins of replication respectively [Taanman, 1999]. The 
mitochondrial proteome is dynamic, i.e. both the precise polypeptide composition and the relative 
abundance of a given polypeptide may vary in mitochondrial proteomes of different tissues as well as in the 
same tissue over time [Mootha et al. 2003]. In the same cell may coexist wild-type (normal) and mutated 
mtDNA, a condition called heteroplasmy [Wallace, 1992]. However, there are highly conserved regions, 
while other regions show a very high variability. 
The overall mutation rate is ten to twenty times higher than the nuclear genome and most of the 
replacements that have been found in mitochondrial DNA are point mutations, with a strong preponderance 
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of transitions (substitutions purine→purine or pirimidine→pirimidine) respect to transvertions (substitutions 
purine→pirimidine or vice versa). Moreover mtDNA is located in the mitochondrial matrix, near the 
mitochondrial respiratory chain, that is a potent source of DNA damaging free radicals. Particularly, the 
control region (CR), also called displacement loop (D-loop, nt 16024-576) [Taanman, 1999], is composed 
of 1121 nucleotides, that are the most sensitive to mutagenesis [Chinnery et al, 1999]. The CR includes the 
L- and H-strand promoters (PL and PH), their mitochondrial transcription factor A (mtTFA) binding sites, the 
downstream conserved sequence blocks (CSB) I, II, and III, and the origins of H-strand replication (OH1 and 
OH2) [Shadel and Clayton, 1997] (Figure 3). In this particular trait three hypervariable sequences are 
present, called HVSI, HVSII and HVSIII, characterized by a high level of mutation, higher than whole 
mtDNA variability, showing a high number of hotspot  [Malyarchuk and Rogozin, 2004].  
 
Figure 3: Schematic representation of the D-loop region (Source: “Does the 
mitochondrial transcription-termination complex play an essential role 
in controlling differential transcription of mitochondrial DNA?”, Selwood 
et al. 2000) 
 
In addition, mtDNA has a high mutation fixation rate, which explains the high level of mtDNA 
substitutions; moreover their relative stability make the d-loop the ideal candidate for the identification and 
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classification of mitochondrial haplogroups, i.e. groups of related individual mtDNA sequences (haplotypes) 
[Kivisild et al, 2005; Torroni et al, 2006]. 
 
 
3. MtDNA variability 
As a direct consequence of the mtDNA features, there are two levels of mtDNA variability: an 
hereditary or inter-individual variability, and a somatic or intra-individual variability. 
Because of solely maternal inheritance, mtDNAs can only evolve by the sequential accumulation of 
mutations along radiating maternal lineages and the number of mutation, that differentiates the mtDNA of 
an individual from that of his ancestor, can be used as a molecular clock, providing a useful tool to the 
phylogenetic reconstruction. 
This means that the human mtDNA is a molecular archive of the history and migration of women who 
have passed on to subsequent generations. If a mtDNA mutation arises and mutation is beneficial in a 
particular environment, it and its descendants will increase in frequency in that environment. Thus, different 
subsets of the variation in mtDNA tend to be confined to different regions and different human populations 
[Torroni et al. 2006]. 
 
3.1 Haplogroups 
Phylogeographic studies of the human mtDNAs have revealed a remarkable correlation between 
mtDNA lineages and the geographic origins of indigenous populations. These regional mtDNA lineages are 
known as haplogroups. The various regional haplogroups form the branches on a single human 
dichotomous mtDNA phylogenetic tree, generated by the accumulation of sequential mtDNA mutations on 
radiating maternal lineages. The human mtDNA tree is rooted in Africa and specific branches were radiated 
into different geographic regions, probably constrained by the climatic zones [Cann et al. 1987, Johnson et 
al. 1983, Merriwether et al. 1991, Wallace et al. 1999] (Figure 4). 
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Figure 4: Diagram outlining the migratory history of the human mtDNA haplogroups (Source:  
http://www.familytreedna.com) 
 
African mtDNAs are the most diverse and thus most ancient, with an overall age of about 150,000 to 
200,000 years before present (YBP). African mtDNAs fall into four major haplogroups: L0 (oldest), L1, L2, 
and L3 (youngest). L0, L1, and L2 represent about 76% of all sub-Saharan African mtDNAs and are 
defined by a HpaI restriction site at np 3592. In northeastern Africa, two mtDNA lineages, M and N, arose 
from L3 about 65,000 YBP. These mtDNA lineages left sub-Saharan Africa and radiated into Eurasia to 
give all of the Eurasian mtDNAs. In Europe, haplogroups L3 and N gave rise to haplogroups H (about 45% 
of European mtDNAs), T, U, V, W, and X (about 2%) as well as I, J (about 9%), and K (Uk). Europeans 
separated from Africans about 40,000–50,000 YBP. In Asia, lineages M and N radiated to give rise to, 
starting from N, haplogroups A, B, F and from M, haplogroups C, D, G [Wallace et al. 1999]. 
As Asians migrated northeast into Siberia, haplogroups A, C, D became progressively enriched, 
such that they became the predominant mtDNA lineages in the indigenous peoples of extreme 
northeastern Siberia, Chukotka. When the Bering land bridge appeared, about 20,000 to 30,000 YBP, 
people harboring these mtDNA haplogroups were in a position to migrate into the New World, where they 
founded the Paleo-Indians. After the land bridge submerged, haplogroup G arose in Central Asia and 
moved into northeastern Siberia to populate the area around the Sea of Okhotsk. Later, a migration 
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carrying haplogroup B started from eastern Central Asia and moved along the coast to the New World, by-
passing Siberia. Haplogroup B then mixed with A, C, and D in southern North America, Central America, 
and northern South America to generate the Paleo-Indians. In addition, haplogroup X was brought to the 
New World in a migration that took place about 15,000 YBP. These immigrants settled in the Great Lakes 
region, and haplogroup X mtDNAs are found in 25% of the Ojibwa mtDNAs today. Since haplogroup X is 
found primarily in northeastern Europe, it has been speculated that an ancient European migration carrying 
this haplogroup might also have contributed to the Paleo-Indian populations, perhaps bringing the 
progenitors of the Clovis lithic culture to the Americas [Wallace et al. 1999]. 
Later migrations from northeastern Siberia, carrying a modified lineage of haplogroup A, founded the 
Na-Déné populations about 9500 YBP. More recently, immigrants from Siberia bearing derived lineages of 
haplogroups A and D moved along the Arctic Circle to found the Eskimos and Aleuts [Wallace et al. 1999]. 
Analysis of the mtDNA nucleotide variants revealed three different categories of variants: (a) neutral, 
including synonymous and weakly conserved nonsynonymous amino acid substitutions; (b) deleterious, 
altering highly conserved amino acids but located at the tips of the branches of the tree, indicating they are 
recent; and (c) adaptive, altering highly conserved amino acids but located within the internal branches of 
the tree, indicating that they are ancient. It is supposed that the mutations in class (c) are adaptive because 
they alter highly conserved amino acids, yet they have persisted in the face of intense purifying selection 
for tens of thousands of years. Hence, as these variants are not neutral or deleterious, they must be 
adaptive [Wallace, 2005]. 
 
3.2 Point mutations of mtDNA 
Because of the proximity of the respiratory chain, source of ROS, and the limited ability to correct 
errors of the enzyme deputy to the replication of mtDNA, polymerase γ [Kaguni 2004; Kujoth et al. 2005; 
Johnson et al. 2001], the polymorphisms and single base mutations in mtDNA are very frequent. 
The identification of systemic diseases caused by mtDNA mutations supported the hypothesis that 
mtDNA mutations might be a key factor in aging and age related degenerative diseases [Wallace et al. 
2005]. Pathogenic mtDNA mutations fall into three categories: rearrangement mutations [Holt et al. 1988], 
polypeptide gene missense mutations [Wallace et al. 1988a], and protein synthesis (rRNA and tRNA) gene 
mutations [Shoffner et al. 1990, Wallace et al. 1988b]. The number of mtDNA-associated diseases 
identified increased quickly, hence it is thought that mitochondrial diseases commonly have a delayed 
onset and progressive course and that they result in the same clinical problems as observed in age-related 
diseases and in the elderly. Clinical manifestations that have been linked to mtDNA mutations affect the 
brain, heart, skeletal muscle, kidney, and endocrine system, the same tissues affected in aging. Specific 
symptoms include dementias, cardiovascular disease, muscle weakness, forms of blindness, deafness, 
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movement disorders, renal dysfunction, and endocrine disorders including diabetes [DiMauro and Schon, 
2003; Wallace, 1999; Wallace and Lott, 2002; Wallace et al, 2001; http://www.mitomap.org]. 
 
3.2.1 Pathogenic mtDNA rearrangement mutations 
MtDNA rearrangement mutations can be either inherited or spontaneous. Inherited mtDNA 
rearrangement mutations are primarily insertions. The first inherited insertion mutation identified caused 
maternally inherited diabetes and deafness [Ballinger et al. 1992 and 1994].  
Spontaneous rearrangement mutations, above all deletions, generally result in a related spectrum of 
symptoms, irrespective of the position of the deletion end points. This is because virtually all deletions 
remove at least one tRNA and thus inhibit protein synthesis [Moraes et al. 1989]. Therefore the nature and 
severity of the symptoms from mtDNA deletion rearrangements is not a consequence of the nature of the 
rearrangement, but rather of the tissue distribution of the rearranged mtDNAs. Of all the deletions, the most 
often found, and that removes all or part of 7 of the 13 proteins encoded by mtDNA and 5 of the 22 tRNA 
genes, regardless of phenotype, size 4977 bp and is commonly referred to as ―common deletion‖, which 
seems to be flanked by direct repeats of 13 bp [Gadaleta et al. 1992; Lee et al. 1997]. A lethal childhood 
pancytopenia, known as Pearson marrow pancreas syndrome, is caused by widely disseminated 
rearrangements that prevent bone marrow stem cells from proliferating. Mitochondrial myopathy with 
ragged red fibers (RRF), instead, results by widely distributed mtDNA rearrangements that spare the bone 
marrow. Mitochondrial myopathy is frequently associated with ophthalmoplegia and ptosis, which is 
referred to as chronic progressive external ophthalmoplegia (CPEO) and, when the case is more severe, 
with multisystem involvement, it is the Kearns-Sayre syndrome (KSS) [Wallace and Lott, 2002]. 
 
3.2.2 Pathogenic mtDNA missense mutations 
Missense mutations are substitutions of a single base that give rise to a codon encoding a different 
amino acid. Missense mutations in mtDNA polipeptide genes can also result in an array of clinical 
manifestations. For example, a mutation at np 8993 (T>G), in the mtDNA ATP6 gene, is associated with 
neurogenic muscle weakness, ataxia, and retinitus pigmentosum (NARP), when present at lower 
percentages of mutant [Holt et al. 1990], and lethal childhood Leigh syndrome when present at higher 
percentages of mutant [Tatuch et al. 1992]. This mutation causes a marked inability of the ATP synthase to 
utilize the electrochemical gradient to make ATP [Trounce et al. 1994] with a consequent increase in 
mitochondrial ROS production [Mattiazzi et al. 2004]. 
Progressive muscle weakness has been increasingly linked to missense and nonsense mutations in 
the cytb gene [Andreu et al. 1999; Dumoulin et al. 1996]. Rare nonsense or frameshift mutants in COI have 
been associated with encephalomyopathies [Bruno et al. 1999; Comi et al 1998]. 
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Missense mutations in complex I genes have been linked to Leigh syndrome [Solano et al. 2003], 
generalized dystonia and deafness [Jun et al. 1994], and to Leber hereditary optic neuropathy (LHON), a 
form of midlife, sudden-onset blindness [Brown et al. 2000 and 2001; Wallace et al. 1988]. LHON is a 
particular disease because the mutations in ND genes produce very different conserved amino acids 
changes, resulting in varying severities of complex I defects [Brown et al. 2000]. This anomaly has been 
explained by the discovery that the mildest LHON mtDNA mutations, particularly those in ND6 at np 14484 
and ND4L at np 10663, are usually found on a particular mtDNA background, the European mtDNA lineage 
J [Brown et al. 1997 and 2001]. Lineage J mtDNAs have been found to harbor mtDNA missense mutations 
that partially uncouple OXPHOS, thus exacerbating the ATP defect of the pathogenic mutations [Ruiz-
Pesini et al. 2004]. 
 
3.2.3 Pathogenic mtDNA proteins synthesis mutations 
Base substitutions in mtDNA protein synthesis genes can also result in multisystem disorders with a 
wide range of symptoms, including mitochondrial myopathy, cardiomyopathy, dementia, diabetes, intestinal 
dysmotility, deafness, mood disorders, movement disorders.  
The most common mtDNA protein synthesis mutation is at np 3243 (A>G) in the tRNALeu gene 
[Goto et al. 1990]. This mutation has a wide variability in its clinical manifestations. When present at 
relatively low levels (10%–30%) in the patient‘s blood, the patient may manifest only type II diabetes with or 
without deafness [van den Ouweland et al. 1994]. By contrast, when the A3243G mutation is present in 
>70% of the mtDNAs, it does not cause diabetes, but instead causes the MELAS syndrome, with more 
severe symptoms such as short stature, cardiomyopathy, CPEO, and mitochondrial encephalomyopathy, 
lactic acid and stroke-like episodes [Goto et al. 1990]. 
Moreover Shoffner et al. (1990) and Wallace et al. (1988) have seen that, in myoclonic epilepsy and 
ragged red fiber (MERRF) disease, the level of mutant heteroplasmy of the tRNALys np 8344 A to G 
mutation plus the age of the patient influence the severity of the clinical symptoms. 
 
3.3 A special case: C150T 
MtDNA mutations can influence the proper functioning of the cell and the energy state, and result in 
a variability in the disease incidence. 
Mutations localized in the non-coding control region (CR) require a separate argument to justify their 
presence. In fact, these mutations do not produce defective polypeptides and therefore do not act directly 
on the respiration affecting the ATP/heat production or the ROS production. Even so the potential 
importance of these mutations is even higher, since they may act on the regulation of the mtDNA gene 
expression.  
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Michikawa et al. (1999) reported that some mutations in the CR, as T414G, T408A, A189G, 
accumulate with age in specific tissues, and most recently a C150T mutation has been identified in 
lymphocytes of centenarians and twins [Zhang et al. 2003] (Figure 5). The C150T seems to be particularly 
interesting because it is localized next to one of the main origins of mtDNA H-strand replication (situated in 
position 151). Zhang et al. (2003) proposed that the mutation conferred some mtDNA replicative 
advantages, but they could only demonstrate that it shifted the position of the origin from 151 to 149. On 
the contrary, Fish et al. (2004) have observed that the C150T mutation inactivates the origin close to it, 
while the mtDNA tries to compensate by enhancing the activity of the origin in position 191. So, a decrease 
of activity for the origin near 150 could actually justify more easily the association with longevity from the 
point of view of performances/life span. In this case, less mtDNA could be related to a lower respiratory 
activity, granting a slightly lower physical performances and a concomitant lower oxidative stress at the 
cellular level. However, such a speculation has to take into account the recent hypothesis that the ―real 
origin‖, which generates complete mtDNA chains would be in position 57, while other origins previously 
known as reserves would have a role in forming the 7S DNA [Fish et al. 2004]. 
 
 
Figure 5: Position of the C150T mutation in the D-loop and other tissue-specific aging-
dependent somatic mutations (Source: “Strikingly higher frequency in 
centenarians and twins of mtDNA mutation causing remodeling of replication 
origin in leukocytes”, Zhang et al. 2003) 
 
Zhang et al. (2003) argue that the somatic event in or near the 150 position could lead to a general 
remodeling of the entire system of replication, probably controlled by the nucleus. Therefore this 
remodeling could accelerate mtDNA replication, to compensate the oxidative damage of the same DNA 
and its functional deterioration occurring in old age. The age-dependent accumulation of point mutations 
with age, previously identified in fibroblasts and skeletal muscle in critical sites for mtDNA replication, can 
be considered part of the remodeling. 
The data also showed that C150T variant causes a remodelling of the replication origin at position 
151 and can be either inherited (polymorphism) or somatically acquired (mutation). It also may cause an 
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activity decreasing. Coskun et al. (2003) suggested that mtDNA haplogroups are likely not neutral and that 
C150T variant associated with haplogroup J [De Benedictis et al, 1999] might have changed oxidative 
phosphorylation efficiency (OXPHOS) by reducing the activity. Moreover J haplogroup is associated to the 
presence of at least four mutations close to replication origins, including C150T [Niemi et al., 2005]. Such 
observation suggests that functional mutations in the CR may interact with mtDNA haplogroups and 
indirectly support the traditional model of replication against the new symmetric model, which reduces OH to 
a simple point of arrest [Raule et al. 2007]. 
 
The result of heteroplasmic mutations depends on several factors, including type and location of the 
variation, replication rate of the cell, and also chance since the mutant molecules can be randomly lost as a 
consequence of mitochondria replicative segregation. In any case, since mutations are stochastic events, 
mtDNA heteroplasmy tends to increase with age. 
Usually, a low level of heteroplasmy does not impair mitochondrial function, but once the level of 
mutant mtDNA exceeds a certain threshold, OXPHOS dysfunction may arise [DiMauro et al. 2003 and 
2005]. The cell tries to cope with such a stressful condition by increasing OXPHOS, and therefore 
producing ROS, in a vicious circle that may become lethal to the cell itself. 
In general, the age-related accumulation of mtDNA somatic mutations leads to a decline in 
mitochondrial function, which contributes to aging and degenerative diseases [Linnane et al. 1989; 
Wallace, 2005]. In fact, most of the literature on mtDNA somatic mutations reports data on the role played 
by mtDNA heteroplasmy on age-related diseases.  
The study by Zhang et al. (2003) is of great value because it indicates a possible beneficial effect on 
longevity by a mtDNA somatic mutation able to restore the mitochondrial replication machinery. Therefore, 
it seemed worthwhile to further investigate possible links between mtDNA CR heteroplasmy and longevity. 
Since longevity shows clear patterns of familiarity [Cournil and Kirkwood, 2001; Hjelmborg et al. 2006], the 
study of such a heteroplasmy in relatives of centenarians may help to clarify the role of mtDNA somatic 
variability in longevity. In particular, Rose et al. (2007 and 2010) argue that the patterns of mtDNA CR 
heteroplasmy do not differ between centenarians and their descendants, but differ between relatives of 
centenarians and age-matched controls. These results show that mtDNA CR heteroplasmy cannot be 
accounted for only by to age-related stochastic mutations. What is more, the finding that mtDNA CR 
heteroplasmy is greater in descendants of centenarians than in age-matched controls suggests a beneficial 
role of mtDNA heteroplasmy for attaining longevity. In fact, several data show that the offspring of 
centenarians have a better chance to attain longevity than the general population [Gudmundsson et al. 
2000; Atzmon et al. 2005]. Recent findings suggest that at least some aspects of the above theory require 
reconsideration [Sato et al. 2006]. In fact, a key for explaining the paradox that mtDNA heteroplasmy could 
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be beneficial for longevity may be the new emerging concept of mitochondria complementation, which 
suggests that human cells are protected from mitochondrial dysfunction by complementation of mtDNA 
products in fused mitochondria [Ono et al. 2001]. The beneficial effect of complementation may be 
enhanced by efficient mtDNA replication, as provided by CR mutations which introduce alternative 
replication sites. In fact, multiple replication origins falling in D-loop region could play a major role in 
accelerating mtDNA synthesis to satisfy developmental, physiological, or aging-related demands [Fish et al. 
2004]. However, neither the replicative advantage of some variants nor the mitochondrial complementation 
can explain, by themselves, the heteroplasmy patterns. By contrast, it is likely that the interplay among new 
replication origins, mitochondrial complementation and nuclear factors might provide an advantage for 
pursuing longevity by counteracting age-related mitochondrial damages [Rose et al. 2007]. In this frame, 
the subjects who are genetically predisposed to mtDNA CR heteroplasmy would be clearly favoured in the 
demographic selection [Perls et al. 2002]. 
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Chapter 4 
 
AIM OF THE STUDY 
 
 
As discussed in the previous chapters, Down Syndrome (DS) is a genetic disorder in which multiple 
major aspects of the senescent phenotype occur much earlier than in karyotypically normal age-matched 
subjects. 
In particular, in DS there is an acceleration of aging process of the Central Nervous System, with an 
early decline in the already reduced cognitive ability similar to that seen in Alzheimer's disease (AD). The 
trisomy 21 also leads to a dose-dependent increase in the production of the amyloid protein precursor 
(APP), as the gene for APP is located on chromosome 21 and, consequently, in the production of 
amyloidogenic fragments causing an early and predominant formation of senile plaques, typical of AD. It is 
known that oxidative damage and neuroinflammation interact with each other, accelerating the progress of 
the disease particularly in persons with Down syndrome over 40 years showing that inflammation is a 
driving force in the neuropathology of AD in subjects with Down syndrome. In addition, some genes and 
some allelic variants are associated with age-related neurodegeneration and the AD. In particular, APOE ε4 
allele is recognized as a risk factor for the AD. 
The aim of this study is to analyze an integrated set of molecular genetic parameters (sequencing of 
the entire mtDNA, heteroplasmy of the control region of mtDNA, haplotypes of APOE), in order to 
understand whether they are associated to early neurocognitive decline in the DS and consequently if they 
can be considered risk factors for such a decline. In particular, the study will aim to: 
a. sequencing the entire mtDNA (16,569 bp) in all DS and in their mothers (DSM) and 
brother/sister (DSS) to identify specific mtDNA mutations; 
b. quantify the level of heteroplasmy around the position 150 of the D-loop, previously 
associated with longevity; 
c. genotype all subjects DS, mothers and brothers for APOE ε4 allele, known neurocognitive 
risk factor; 
d. correlate genetic data with the cognitive status of these people, that has been carefully 
assessed by using a battery of tests designed for people with learning disabilities. 
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Chapter 5 
 
MATERIALS AND METHODS 
 
 
1. Samples 
Taking into account that the mtDNA is inherited only from the mother in both boys and girls, maternal 
mtDNA becomes a reference and a standard (and therefore the better control) to detect any differences or 
mutations that have occurred and have accumulated with age in the mtDNA of the son/daughter with DS. 
Any collection of samples of brother or sister of the DS subjects (with no DS) represents a further 
check on the presence of mutations in mtDNA. Whatever the sex of the subject in question is not relevant 
because only the mother is responsible for inheritance of mtDNA. 
For this reason, the study population is represented by the following groups of subjects (141 subjects 
in total): 
 53 subjects affected by Down Syndrome (DS); 
 the mother of each subject DS (DSM), for a total of 47 subjects; 
 the siblings of each subject DS (DSS) of comparable age/gender, for a total of 41 subjects. 
 
 
2. General protocol 
All subjects were recruited through the collaboration of Department of Experimental Pathology 
(University of Bologna), Institute of Pediatric Medical and Surgical Science of S.Orsola-Malpighi Hospital 
(University of Bologna) and the organization CEPS (Emilian Center Onlus Social Problems for Trisomy 21 ) 
of Bologna. 
Were excluded subjects with an acute pathology in place; patients with hepatic, renal, or cardiac 
deficiency; patients with associated mitochondrial disease (extremely rare situation); patients who have 
taken two months before the recruitment multivitamin or other antioxidants. 
For each subject, given informed consent and by using appropriate questionnaires, with a section 
reserved to the mother and brother, were collected the following data: 
- recent and remote medical history, with particular attention to the presence of the diseases 
most commonly found in the DS and its treatment programs; 
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- socio-economic history, with particular focus on the social and work integration of DS subject 
and to the care pathways in the area; 
- auxologic parameters, more specifically weight (P), height (H), head circumference (CC), 
abdominal circumference (AC), body mass index (BMI) and their percentiles; 
- neurological exam, neuropsychological and neuropsychiatric evaluation of the cognitive and 
language in relation to different ages, through the use of ladders and specific tests; 
- compilation of the questionnaire DSQIID (Dementia Screening Questionnaire for Individuals 
with Intellectual Disabilities) to identify predictors of dementia; 
- blood sampling (10-12 cc) to assess not only the main biochemical parameters commonly 
measured in the follow-up of the DS, but also specific biomarkers of antioxidant capacity and 
levels of oxidative stress and to extract the total DNA, on which three molecular studies were 
carried out, in particular complete sequencing of mtDNA, D-loop heteroplasmy, APOE 
genotyping. 
 
 
3. Purification of DNA 
The QIAamp 96 DNA Blood Kit (QIAGEN) was used for DNA extraction from whole blood. The kit 
combines the selective binding properties of a silica-gel membrane with a high-throughput 96-well format 
and allows simultaneous processing of up to 192 samples. The procedure is the following (Figure 1): 
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Figure 1: procedure for the purification of DNA 
 
 Pipet 20 μl QIAGEN Protease stock solution into the bottom of the collection microtubes.  
 Add 200 μl whole blood to the collection microtubes by touching the insides of the tubes without 
wetting the rims.  
 Add 200 μl Buffer AL to each sample, taking care not to wet the rims of the collection microtubes. 
Seal the tubes using the caps for collection microtubes. 
 Cover the rack with the plastic cover supplied, and mix thoroughly by shaking vigorously for 15 s. 
For efficient lysis, it is essential that the samples and Buffer AL are mixed immediately and 
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thoroughly to yield a homogeneous solution. Hold the racked collection microtubes with both hands 
and shake up and down vigorously. 
 Centrifuge briefly at 3000 rpm to collect any solution from the caps. 
 Incubate at 70°C for at least 10 min in an incubator or oven. 
 Centrifuge briefly at 3000 rpm to collect any lysate from the caps 
 Remove the caps and add 200 μl ethanol 100% to each tube.  
 Seal the tubes using new caps for collection microtubes. Shake vigorously for 15 s. 
 Centrifuge briefly at 3000 rpm to collect any solution from the caps 
 Place QIAamp 96 plate on top of an S-Block. 
 Carefully apply the mixture (620 μl per collection microtube) to the QIAamp 96 plate 
 Seal the QIAamp 96 plate with an AirPore Tape sheet. Centrifuge at 4500 rpm for 6 min. 
 Remove the tape. Carefully add 500 μl Buffer AW1 to each well. 
 Seal the QIAamp 96 plate with a new AirPore Tape sheet. Centrifuge at 4500 rpm for 4 min. 
 Remove the tape. Carefully add 500 μl Buffer AW2 to each well. 
 Centrifuge at 4500 rpm for 25 min at 40°C. The heat generated during centrifugation ensures 
evaporation of residual ethanol in the sample (from Buffer AW2) that might otherwise inhibit 
downstream reactions. 
 Place the QIAamp 96 plate on top of a rack of elution microtubes. 
 To elute DNA, add 150 μl Buffer AE, equilibrated to room temperature, to each well. Seal the 
QIAamp 96 plate with a new AirPore tape sheet and incubate for 1 min at room temperature. 
Centrifuge at 4500 rpm for 7 min. 
 
 
4. Quantification of DNA 
The extracted DNA was quantified with Quant-iTTM dsDNA Broad Range Assay Kit, using the  
PicoGreen®, an ultra sensitive fluorescent nucleic acid stain for quantitating double-stranded DNA (dsDNA) 
in solution. 
Before starting the experiment, it is necessary to prepare a working solution of the Quant-iT™ 
dsDNA BR reagent by making a 200-fold dilution of the concentrated DMSO solution in TE. For example, to 
prepare enough working solution to assay 96 samples in a 12 mL final volume, add 60 μL Quant-iT™ 
dsDNA BR reagent to 12 mL TE. The kit provides pre-diluted DNA standards, which are λ DNA standards 
with a concentration of 0, 5, 10, 20, 40, 60, 80, and 100 ng/µL. Ninety-six samples are quantified in a 384-
well plate, because each sample is quantified in double (Figure 2), and into each well are dispensed 48 µL 
of working solution and 2 µL of each unknown DNA sample. 
49 
 
 
 
Figure 2: preparation of the 384-well plate for the quantification of DNA 
 
The entire protocol has been automated with the MICROLAB STAR workstation (Hamilton Robotics), 
equipped with 16 channels and able to arrange all the operations, reducing time and manual errors. 
After dispensing standards and samples, there is a 5 minutes of incubation at room temperature and 
protected from light, then we proceeded to read with fluorimetric λ excitation of 480 nm and λ emission at 
520 nm using a fluorometer SynergyTM HT (Bio-Tek Instruments, Winooski, Vermont; software KC-4). The 
concentration of the samples was extrapolated from the intensity of fluorescence for each sample reported 
on the standard curve, constructed with the given dilution of standard DNA, after subtraction of white to 
each reading. 
 
 
5. Complete sequencing of mtDNA 
The general scheme for the complete sequencing of mtDNA is as follows: 
 Amplification of mtDNA (16569 bp) with 46 pairs of primers  
 Agarose gel electrophoresis 
 PCR clean-up reaction using ExoSAP-IT® 
 Sequencing reaction 
 Sequencing clean-up reaction 
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 Sequences analysis with SeqScape v2.5 software (Applied Biosystems) in order to 
compare each sequence with the Cambridge Reference Sequence and to attribute a 
subhaplogroup 
 
PCR amplification 
Forty-six pairs of primers (See Appendix), which are specific for the mtDNA and possessing at 5‘ the 
M13 universal primer useful for the following sequencing reaction, are used for complete mtDNA 
amplification reaction. 
Amplification is performed in a 25 µl volume. Each amplification contains at final concentration: 
 
REAGENTS [STOCK] [FINAL] VOLUME (μl) 
Buffer 10X 1X 2,5 
MgCl2 50 mM 1,5 mM 0,75 
dNTPs 100 mM 250 μM 0,5 
Taq 5U/μl 0,06U/μl 0,3 
Primers 50 μM 1,25 μM 4 
DNA 60 ng/μl 15 ng 0,4 
ddH2O  / / 16,55 
FINAL VOLUME     25 
 
The PCR cycling profile (using Biometra T1 Thermocycler) is as follows: 
 
Temperature Time Cycle number 
95°C 3 min 1 
95°C 
60°C 
68°C 
40 sec 
40 sec 
2 min 
30 
68°C 5 min 1 
 
Agarose gel electrophoresis 
It is very important to verify the amplification on an agarose gel 1.5%. Materials we need are:  
 1.5% agarose gel made up with standard 1X TBE (see Appendix) 
 Gel red solution if this has not been pre-incorporated into the gel 
 Tracking dye (Bromophenol Blue + glycerol) 
In each well pipet 1.2 μl of the PCR reactions and 8.8 μl (6.2 μl H2O and 2.6 μl BF6X) to reach a 
volume of 10 μl. Load in a well a marker which contains a mix of known fragments and used to compare our 
bands. Run the gel at 150 V for half an hour. 
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PCR clean-up 
The clean-up reaction is important because it purify PCR products from primers or nucleotides not 
incorporated. For PCR clean-up add 2 μl of Exosap-IT® (directly to PCR product) each 5 μl of PCR product 
(Figure 3). We experimented that only 1 μl of ExoSAP each 25 μl PCR product is sufficient and it allows to 
reduce costs. ExoSAP-IT® (USB, PN 78200) is a mix containing two enzymes: an exonuclease (ExoI) that 
degrades residual single-stranded primers and any extraneous single-stranded DNA produced by PCR, and 
a shrimp alkaline phosphates (SAP) that hydrolyzes remaining dNTPs from the PCR mixture which could 
interfere with the sequencing reaction. 
 
 
Figure 3: PCR clean-up 
 
The PCR cycling profile (using Biometra T1 Thermocycler) is as follows:  
1. activation of enzyme at 37°C for 30 min 
2. inactivation at 80°C for 15 min 
 
Sequencing reaction 
The laboratory method involves the use of the sequencing kit developed by Applied Biosystems, 
which includes the BigDye Terminator v.3.1 Ready Reaction Cycle Sequencing Kit, a reaction mixture 
containing: Taq polymerase, MgCl2, dNTPs and ddNTPs, and universal primers M13 Forward (5‘-
TGTAAAACGACGGCCAGT-3‘) or M13 Reverse (5‘-CAGGAAACAGCTATGACC-3‘), for two parallel 
amplifications, each using one of the two primers. 
The reaction is performed in a 10 µl volume. Each reaction contains at final concentration: 
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REAGENTS [STOCK] [FINAL] VOLUME (µl) 
Buffer 5X 
(Applied Biosystems) 
5X 0.8X 1.6 
Big Dye Terminator v.3.1 
(Applied Biosystems) 
8 µl in a total 
volume of 20 µl 
per reaction 
1 µl 0.8 
Primers M13 Forward or 
M13 Reverse 
100 µM 0.32 µM 1 
Cleaned-up PCR product / / 2 
Water / / 4,6 
Final volume 10 
 
The thermal cycling profile is as follows: 
 
Temperature Time Cycle number 
96°C 1 min 1 
96°C 
50°C 
60°C 
10 sec 
5 sec 
4 min 
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The BigDye Terminator reagent contains a mix of nucleotides. Free bases that match the template 
sequence can attach to the new strand‘s growing (3‘) end, but among all the free bases swimming in the 
solution, there are a few having a chemical fluorescent part, i.e. dye. When the coloured bases attach to 
the growing strand, the extra chemical part keeps the new DNA strand from growing any further. A different 
coloured dye is attached to each of the four kinds of bases. 
A completed sequencing reaction contains an array of coloured DNA fragments. The shortest are 
the length of the primer plus one coloured base. The longest fragments are usually between 500 and 800 
bases long, which is when the sequencing reaction runs out of steam. 
 
Sequencing clean-up reaction 
To perform the sequencing clean-up reaction, it is important to add in each well of the sequencing 
96-plate the following reagents: 
 2 µl of sodium acetate (NaAc) (See Appendix); 
 50 µl Ethanol 100% stored at –20°C, in order to precipitate sequenced fragments; 
 Incubate at room temperature for 10 min; 
 Spin the plate at 1100 xg for 40 min; 
 Remove cover and invert onto paper towel and spin at 100xg for no more than 1 min 
 70 µl Ethanol 70% stored at –20°C  
 Spin at 1100 xg for 14 min; 
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 Remove cover and invert onto paper towel and spin at 100xg for no more than 1 min; 
 Store the plate at 37°C for at least 1h in order to evaporate all the ethanol; 
 Resuspend all wells with 10µl Hi Di Formamide (denaturing agent which allows to maintain a 
denaturing state for capillary elechtrophoresis); 
 Denaturing at 95°C for 2 min. 
 
 
5.1 Analysis at ABI3730 sequencer 
The sample are then loaded on the automatic sequencer (ABI3730, 48 capillaries). Inside the 
sequencer the separation of the fragments depends on their molecular weight, process called capillary 
electrophoresis. The sequencing machine sets up an electric field; all the DNA moves down through a 
porous gel toward the positive charge. Shorter fragments of DNA move more quickly through the matrix of 
the gel than larger fragments do (Figure 4). 
In the sequencing machine, a laser excites the fluorescent dyes, and a camera detects the lights that 
the excited dyes emit. One by one, the sequencing machine reads the DNA molecules passing down the 
gel, and sends the information to a computer. Each nucleotide have a different emission spectrum allowing 
to identify different bases. 
A computer program integrates the information from individual sequencing reactions. It spots where 
fragments overlap, to puzzle the pieces back together.  
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Figure 4: principle of sequencing function. The sequencing fragments 
obtained pass through a laser, while a system provides to record 
the energy emitted by the excited fluorescent molecule. 
 
Many overlapping sequencing reads are needed to reveal the uninterrupted sequence of the original 
stretch of DNA. Some stretches of DNA are easier to read and need to be sequenced a little less often to 
get high-quality sequence. Some stretches need to be analyzed more exhaustively to get finished high-
quality sequence. 
The sequencer gives data in electropherogram form, through a file (.ab1) that shows four different 
peaks (green for adenine, red for timine, blue for cytosine and black for guanosine) and the height of each 
peak depends on the detected intensity. 
We can read files .ab1 with the software SeqScape v2.5 (Applied Biosystems) which allows the 
alignment, the assembling of the overlapping fragments and a comparison with the Cambridge Reference 
Sequence (Figure 5). 
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Figure 5: Image of an analysis with Seqscape. The Cambridge reference sequence is in brown, coloured peak 
represent all the four nitrogenous bases and the green bars indicates the quality of the peak relative to the 
background noise. 
 
 
5.2 Automated procedure 
We have automated the amplification reaction with the MICROLAB STAR workstation, equipped with 
16 channels and able to arrange all the operations, reducing time and manual errors. The platform can 
prepare reactions for 4 different samples, can distribute the reagent mix (manually prepared) in each well 
and the 46 different primers stored in plates. (Figure 6). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6: robotic platform and the localization of all components and reagents. 
 
Blue plate (-20°) + 
BioPlastic (96) plate 
White plate (+4°) 
 +  
Eppendorf 2 mL 
1 
7 
13 
19 
Filter tips 
300 (stf) 
Filter tips 10 
(ltf) 
Blue plate (-20°) +   
Primers (46) plate 
Blue plate (-20°) + 
BioPlastic (96) plate 
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6. Assignment of subhaplogroups 
The complete sequencing of mtDNA allowed us to assign to each sample its haplogroup, following 
Phylotree (http://www.phylotree.org/) [van Oven and Kayser, 2009], a phylogenetic tree of global human 
mtDNA variation (Figure 7), based on both coding and control region mutations, and including the most 
updated haplogroup nomenclature. This mtDNA tree is meant as a framework for evolutionary 
anthropologists, medical geneticists, genealogists and forensic geneticists. The tree is updated at least 
every six months with data related to new published complete mtDNA sequences. This information about 
haplogroup classification allows us to confirm the kinship between DS, DSM and DSS. 
 
 
Figure 7: phylogenetic tree of the Phylotree reference database 
 
 
7. Complete sequencing of mtDNA by Long-PCR 
PCR amplification 
The protocol for the complete sequencing of mtDNA was implemented from another protocol, which 
included the use of a new taq, the Expand Long Range Taq (Roche), and of only four primers (2 forward 
primers and 2 reverse primers) for the amplification of entire mtDNA. In fact this taq is optimized to 
efficiently amplify large genomic DNA fragment from 5 kb to 25 kb in combination with a threefold higher 
fidelity than Taq DNA polymerase. 
Amplification was performed in a 25 µl volume, using the following pairs of primers: 
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• LONG FW1 (5‘-ACATAGCACATTACAGTCAAATCCCTTCTCGTCCC-3‘) and  
LONG RV1 (5‘-ATTGCTAGGGTGGCGCTTCCAATTAGGTGC-3‘); 
• LONG FW2 (5‘-TCATTTTTATTGCCACAACTAACCTCCTCGGACTC-3‘) and  
LONG RV2 (5‘-CGTGATGTCTTATTTAAGGGGAACGTGTGGGCTAT-3‘). 
 
Each amplification contains at final concentration: 
 
REAGENTS [STOCK] [FINAL] VOLUME (μl) 
Buffer with MgCl2 5X 1X 5 
dNTPs mix 10 mM/each 500 μM 1,25 
Primers 10 μM 0,3 μM 0,75 
DNA 30 ng/μl 300 ng 3 
Taq 5U/μl 3,5U/µl 0,35 
ddH2O / / 13,9 
FINAL VOLUME 
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The touchdown PCR cycling profile (using Biometra T1 Thermocycler) is as follows: 
 
Temperature Time Cycle number 
92°C 2 min 1 
92°C 
60°C 
68°C 
10 sec 
30 sec 
13 min 
9 
92°C 
60°C 
68°C 
 
10 sec 
30 sec 
13 min 
(with an increment of 10 sec per cycle) 
19 
68°C 7 min 1 
 
Agarose gel electrophoresis 
Amplified products were controlled by 0.8% agarose gel electrophoresis in TBE buffer with gel red 
staining, using 4 µl of PCR product, 2 µl of BF6X and 1 µl of water. 
 
PCR clean-up 
The clean-up reaction is carried out with 2 µl of ExoSAP-IT®, and the PCR cycling profile provides 
for an activation cycle of enzyme at 37°C for 30 min and an inactivation cycle at 80°C for 15 min. 
 
Sequencing reaction 
Also in this case, the laboratory method involves the use of the sequencing kit developed by Applied 
Biosystems, which includes the BigDye Terminator v.3.1 Ready Reaction Cycle Sequencing Kit. Fifty-five 
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primers are used, most of which are taken from the amplification primers for complete mtDNA, while 
fourteen have been redesigned, using the tool http://www.genelink.com/tools/gl-tmres.asp to uniform the T 
annealing, to be more specific (see Appendix). 
 
 
8. Analysis of heteroplasmy 
We analyzed mtDNA CR heteroplasmy in a 300 bp stretch surrounding the 150 position in total DNA 
from whole blood of all the subjects recruited. The studied region in the mtDNA (nt 16531-261) was 
amplified by 5‘-AATAGCCCACACGTTCCCCTTA-3‘ forward primer and 5‘-GCTGTGCAGACATTCAATTG-
3‘ reverse primer in a final volume of 30 µl. Each amplification contains at final concentration: 
 
REAGENTS [STOCK] [FINAL] VOLUME (μl) 
Buffer 10X 1X 3 
MgSO4 50 mM 1,75 mM 2,1 
dNTPs 10 mM 0,2 mM 0,6/each 
Taq 
(Transgenomic) 
5U/μl 2,5 U/μl 0,3 
Primers 10 μM 0,3 μM 0,9/each 
DNA 60 ng/μl 80-100 ng 5 
ddH2O  /  / 15,4 
FINAL VOLUME     30 
 
The touchdown PCR cycling profile (using Biometra T1 Thermocycler) is as follows: 
 
Temperature Time Cycle number 
95°C 2 min 1 
95°C 
61,6°C 
(with a decrement of 0.5°C per cycle) 
72°C 
30 sec 
30 sec 
30 sec 
14 
95°C 
54,6°C 
72°C 
30 sec 
30 sec 
30 sec 
19 
72°C 5 min 1 
 
Then the PCR products were controlled by 2% agarose gel electrophoresis in TBE buffer with gel red 
staining. 
All the PCR products were denatured at 95°C for 5 min, followed by a reannealing from 95° to 65° 
with a rate of 1°C/min inducing heteroduplex formations, and then submitted to DHPLC (Denaturing High 
Performance Liquid Chromatography). The DHPLC is a method of separation on column by using an 
acetonitril gradient in conditions of increasing temperature, partially denaturing, corresponding to the 
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melting temperature of the fragment amplified by PCR. At an optimal temperature, that partially denatures 
the DNA fragments, more than one peak is present on the chromatogram: one peak is for heteroduplex and 
one for homoduplex because they have different retention times due to less helical fraction in 
heteroduplexes (Figure 8). 
We set up a DHPLC protocol in order to quantify the heteroplasmy. We used the WAVE 3500HT 
machine with 6.5 x 37 mm DNASep Cartridge (Transgenomic), a mutation detection method with an elution 
rate of 0,9 mL/min in the column (normal course) with a melting temperature of 60°C, a time shift of 2 
minutes. We have set other parameters for the analysis: start time of 2-8, detection threshold 0.01, group 
separation 0.01, noise factor 2.0. Mismatches were recognised by the appearance of two or more peaks in 
the elution profile. 
 
 
Figure 8: example of chromatogram 
 
8.1 Quantitative analysis 
To ensure clean results and homospecies peaks it is necessary to use a DHPLC optimized enzyme, 
the Optimase DNA polymerase (Transgenomic). This enzyme has the advantage that it does not need 
additives, which if not eliminated, would cause early column abrasion. Therefore, this Taq should be used 
to avoid false-positive shoulder peaks in front of the homoduplex peaks. Meierhofer et al (2005) has 
demonstrated that Optimase DNA polymerase is necessary to produce clear peaks with high amplitude, 
while other enzymes they tested showed a spectrum of pre-peaks leading to difficultied in detection of low 
level heteroplasmies. 
The phase of chromatogram analysis becomes even more complex in the analysis of mitochondrial 
DNA because it is present in multiple copies within the same cell and in the same mitochondrion, therefore 
a mutation in the mtDNA does not lead to the formation of 50:50 ratio of heteroduplex and homoduplex, as 
it occurs in the genomic DNA. In fact, mutant mtDNA varieties may be present at undetectable low 
concentrations, and the degree of heteroplasmy may be also tissue-specific. Initially we used two different 
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methods: the first was the calculation of the integral of heteroplasmic peak areas, by obtaining the equation 
of a line. The second method was the calculation of the height of heteroplasmic/homoplasmic peaks, 
obtaining a parabolic relationship [Rose et al, 2007]. In order to built a reference curve, used for estimating 
the levels of heteroplasmy in our biological samples, plasmids containing the common C150 and the 
mutant 150T sequences were mixed in different proportions to generate heteroplasmy levels of 0%, 5%, 
10%, 20%, 30%, 40%, 50%. Reporting our results (areas or heights) on the reference curve, both of the 
two methods used seemed not to fit specifically our data. 
Finally, the level of heteroplasmy, that is the percentage of the less frequent allele in the 
heteroplasmic mixture, was calculated as described by Lim et al. (2007). They postulated this universal 
equation: y=(AHET/(AHET + AHOM))*100, which fits better our data. 
It is necessary that the sum of the two heights (homoplasmic and heteroplasmic) is >=20 mV to 
obtain a sensibility of almost 5%. 
 
 
9. APOE genotyping 
APOE genotyping was performed as previously described [Hixson and Vernier, 1990]. The protocol 
provides for the PCR amplification of genomic DNA sequence containing APOE gene. The reaction was 
performed using the following primers: F4 (5‘-ACAGAATTCGCCCCGGCCTGGTACACAC-3‘) and F6 (5‘-
TAAGCTTGGCACGGCTGTCCAAGGA-3‘) described by Emi et al. (1988) in a final volume of 30 µl. Each 
amplification contains at final concentration: 
REAGENTS [STOCK] [FINAL] VOLUME (μl) 
Buffer 10X 1X 3 
MgCl2 50 mM 1,5 mM 0,9 
dNTPs 2,5 mM 0,25 mM 3 
Primers 10 μM 0,3 μM 1/each 
DMSO 100% 10% 3 
DNA 60 ng/μl 200 ng 1 
Taq 5U/μl 1,5 U/μl 0,3 
ddH2O  /  / 16,8 
FINAL VOLUME     30 
 
The PCR cycling profile (using Biometra T1 Thermocycler) is as follows: 
 
Temperature Time Cycle number 
95°C 5 min 1 
95°C 
63°C 
70°C 
1 min 
1 min 
2 min 
45 
70°C 12 min 1 
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Amplified products were controlled by 1.5% agarose gel electrophoresis in TBE buffer with gel red 
staining, using 3 µl of PCR product, 2 µl of XC6X and 5 µl of water. Then amplified products were digested 
overnight at 37°C with 3.5 U of the restriction enzyme HhaI and visualized via ethidium bromide staining on 
4.5% agarose Molecular Screening gel.  
The nucleotide substitution, which leads to Arg or Cys at positions 112 and 158 of the APOE gene 
alters the cleavage site of HhaI: the enzyme acts at GCGC sequences, present at codon Arg residue in 
position 112 (ε4 allele ) and in position 158 (ε3 and ε4 alleles), but is not active on GTGC sequences 
encoding Cys residues in position 112 in ε3 allele and in positions 112 and 158 in ε2 allele. 
The cut to the polymorphic site allows you to assign each sample one of the following genotypes: 
ε2/ε2, ε2/ε3, ε2/ε4, ε3/ε3, ε3/ε4, ε4/ε4 (Figure 9). Except for the band present at 35 bp, which is common to 
all genotypes, each genotype has a unique combination of HhaI fragments: 
 ε2/ε2 contains fragments of 91bp and 81bp, in agreement with the absence of the restriction 
site for the presence of Cys at position 112 and 158; 
 ε3/ε3 contains the fragment of 91bp and 48bp, resulting from cutting at Arg 158; 
 ε4/ε4 contains the fragment of 48bp and 72bp, resulting from cutting at Arg 112. 
 
The heterozygous samples include both sets of fragments from each allele [Appel et al. 1995]. 
 
 
Figure 9: Diagram of the possible genotypes for the polymorphisms of the APOE gene. 
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10. Statistical analysis 
The analysis of the sequences to determine haplogroups and somatic mtDNA variability was carried 
out by SeqScape software v2.5 (Applied Biosystem). 
Mitochondrial sub-haplogroups and genotype frequencies were compared between DS, DSM and 
DSS subjects using the χ2 or Fisher-exact test. 
The mitochondrial subhaplogroups variability envisages at least 40 subhaplogroups, which have 
been further grouped into 6 macro-groups considering their frequencies and phylogenetic relationship. The 
comparison between each of the 6 mtDNA macro-haplogroups in DS, DSM and DSS subjects have been 
computed by applying Pearson‘s Chi-squared test with Yates‘ continuity correction. 
Tests for statistical significance were two-sided with = 0.05; effect size for the association was 
measured as odds ratio (OR) with 95% confidence intervals (CI). 
SPSS v.20 statistical software (SPSS Inc., Chicago, IL, USA) was used for all statistical analyses. 
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Chapter 6 
 
RESULTS 
 
 
1. Samples 
In this study we analyzed genetic factors that might influence the neurocognitive decline observed in 
DS. In particular mtDNA has been analyzed, from both a qualitative and a quantitative point of view; the 
most commonly risk factor for AD, i.e. the APOE ε4 allele, it was also investigated. 
The database consists of 141 subjects distributed as follows: 
 
STATUS N 
Down Syndrome (DS) 53 
Mothers (DSM) 47 
Siblings (DSS) 41 
 
These subjects are distributed this way: 
 37 families in which are present DS, DSM and DSS; 
 10 families where only the DS subject and his/her mother have been recruited; 
 4 families where only the DS subject and his/her brother/sister have been recruited; 
 2 DS subjects, without mother and brother/sister. 
 
Table 1 shows males/females proportion: in our total sample, there is a higher proportion of female 
(72%) subjects, but at least the DS females equal the DSS females; the reason is that in the database 
there are only DS patients and their sibling‘s mothers. 
 
 Males (N=39) Females (N=102) 
 DS (%) DSM (%) DSS (%) DS (%) DSM (%) DSS (%) 
N 26 (66.6) 0 (0) 13 (33.4) 27 (26.5) 47 (46) 28 (27.5) 
Mean-range 29.6 ± 9.9 0 28.4 ± 9.6 27.0 ± 14.9 56.9 ± 9.5 32.1 ± 14.4 
Age-range 16-61 0 13-46 10-70 41-83 12-70 
Table 1: sample distribution and general characteristics of the study participants. 
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The following Figure 1 reports the total number of males and females, while Figure 2 represents the 
age distribution boxplot of participants by status (DS, DSM or DSS). 
 
 
Figure 1: Graphic distribution of DS, DSM and DSS. 
 
 
Figure 2: Age distribution boxplot of participants. 
 
 
2. Distribution of haplogroups 
We obtained the complete mtDNA sequences of the subjects recruited using a protocol that provides 
amplification of entire mtDNA, PCR clean-up reaction using ExoSAP-IT®, sequencing reaction and finally 
sequences analysis with SeqScape v2.5 software (Applied Biosystems). 
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The complete mtDNA resequencing allowed us to classify our samples from DS, DSM and DSS into 
more than 40 haplogroups/sub-haplogroups (see Appendix). Most of these are typical of modern European 
populations, but a sub-Saharan African (L2a1) mtDNA was also detected. This latter finding is not 
unexpected, since low frequencies of African haplogroups are not uncommon in populations of southern 
Europe. However, due to the small number of samples, we have grouped all sequences into macro-
haplogroups (Table 2 and Figure 3). 
 
 DS (N=53) DSM (N=47) DSS (N=41) 
Macro-
haplogroups 
N % SE N % SE N % SE 
HV* (1) 29 54.72 0.0684 27 57.45 0.0721 23 56.09 0.0775 
J 2 3.77 0.0262 1 2.13 0.0211 1 2.44 0.0241 
K 3 5.66 0.0317 2 4.25 0.0294 2 4.88 0.0336 
T 6 11.32 0.0435 5 10.64 0.0450 3 7.32 0.0407 
U 12 22.64 0.0575 11 23.40 0.0618 11 26.83 0.0692 
Other (2) 1 1.89 0.0187 1 2.13 0.0211 1 2.44 0.0241 
Table 2: list of macro-haplogroups with the related frequencies and Standard Error (SE). (1) HV* includes all mtDNAs 
belonging to haplogroups HV, H and V, (2) Other includes L2a1. 
 
 
Figure 3: Distribution of macro-haplogroups 
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The distribution of haplogroups allowed us to confirm the relationship of subjects recruited and to 
compare our frequencies with those previously reported in literature (Table 3) [Richards et al. 2000]; we 
verified that our results correspond with a good approximation to the reference values referred to 
populations, with fluctuations attributable at smallness of our database. 
 
Haplogroup DS DSM DSS Reference (*) 
HV  54.72% 57.45% 56.10% 50.4-54.1% 
 H 43.40% 44.68% 41.46% 44.5-48.2% 
 V 1.89% 2.13% 2.44% 3.9-5.4% 
J  3.77% 2.13% 2.44% 8.3-10.4% 
T  11.32% 10.64% 7.32% 7.2-9.2% 
U  22.64% 23.40% 26.83% 20.1-23.2% 
K  5.66% 4.26% 4.88% 4.9-6.6% 
Other (1)  1.89% 2.13% 2.44% 1.4-2.4% 
(*) Richards et al. 2000 
Table 3: The table shows the haplogrops’ frequencies compared with those 
reported by Richards et al. 2000. (1) Other includes L2a1. 
 
Some differences are present, but none of them reach statistical significance, due to the low 
number of subjects of our experimental group. 
 
 
3. Analysis of mtDNA mutations 
In order to identify whether the neurocognitive decline of DS subjects could be attributed to specific 
mutations of mtDNA, the complete mtDNA sequences of 51 DS were analyzed and compared with those of 
46 DSM and 41 DSS subjects (Table 4). A total of 406 mutated positions were detected in comparison with 
the Reference Cambridge Sequence and analyzed. Of these, 47 (underlined and colored) were not 
previously reported in either MITOMAP (www.mitomap.org) or mtDB (www.genpat.uu.se/mtDB), and 19 of 
them (in bold) are not synonymous and cause an aminoacid change. Moreover, 11 SNPs have an 
heteroplasmy superior to 25%. 
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Nucleotide Position(1) Locus 
Nucleotide 
Change 
Aminoacid 
Change(2) 
DS  
N=51 (%) 
DSM  
N=46 (%) 
DSS 
N=41 (%) 
41 D-loop (HVSII) C>T  non coding 1 (2) 1 (2,2) 0 (0) 
53 D-loop (HVSII) G>A non coding 1 (2) 1 (2,2) 0 (0) 
55 D-loop (HVSII) T>C non coding 1 (2) 1 (2,2) 0 (0) 
72 D-loop (HVSII) T>G non coding 4 (7,8) 4 (8,7) 4 (9,8) 
73 D-loop (HVSII) A>G  non coding 25 (49) 21 (45,7) 19 (46,3) 
93 D-loop (HVSII) A>G non coding 2 (3,9) 2 (4,3) 1 (2,4) 
143 D-loop (HVSII) G>A non coding 1 (2) 1 (2,2) 1 (2,4) 
146 D-loop (HVSII) T>C  non coding 6 (11,8) 4 (8,7) 5 (12,2) 
150 D-loop (HVSII) C>T  non coding 7 (13,7) 7 (15,2) 4 (9,8) 
151 D-loop (HVSII) C>T  non coding 5 (9,8) 2 (4,3) 2 (4,9) 
152et D-loop (HVSII) T+C  non coding 1 (2) 0 (0) 0 (0) 
152 D-loop (HVSII) T>C  non coding 8 (15,7) 11 (23,9) 9 (22) 
185 D-loop (HVSII) G>T non coding 1 (2) 1 (2,2) 1 (2,4) 
189 D-loop (HVSII) A>G  non coding 2 (3,9) 2 (4,3) 2 (4,9) 
195 D-loop (HVSII) T>C  non coding 11 (21,6) 10 (21,7) 9 (22) 
199 D-loop (HVSII) C>T  non coding 1 (2) 0 (0) 1 (2,4) 
204 D-loop (HVSII) T>C  non coding 1 (2) 1 (2,2) 1 (2,4) 
214 D-loop (HVSII) A>G  non coding 1 (2) 1 (2,2) 1 (2,4) 
236 D-loop (HVSII) T>C non coding 1 (2) 1 (2,2) 1 (2,4) 
239 D-loop (HVSII) T>C non coding 2 (3,9) 2 (4,3) 0 (0) 
242 D-loop (HVSII) C>T non coding 1 (2) 0 (0) 1 (2,4) 
249delA D-loop (HVSII) del non coding 1 (2) 1 (2,2) 0 (0) 
252 D-loop (HVSII) T>C non coding 2 (3,9) 2 (4,3) 2 (4,9) 
253 D-loop (HVSII) C>T non coding 0 (0) 1 (2,2) 0 (0) 
263 D-loop (HVSII) A>G  non coding 50 (98) 43 (93,5) 40 (97,6) 
279 D-loop (HVSII) T>C  non coding 1 (2) 1 (2,2) 1 (2,4) 
295 D-loop (HVSII) C>T non coding 2 (3,9) 1 (2,2) 1 (2,4) 
296 D-loop (HVSII) C>T non coding 1 (2) 1 (2,2) 1 (2,4) 
310 D-loop (HVSII) T>C  non coding 0 (0) 0 (0) 1 (2,4) 
324 D-loop (HVSII) C>G  non coding 0 (0) 1 (2,2) 0 (0) 
456 D-loop (HVSII) C>T non coding 3 (5,9) 1 (2,2) 3 (7,3) 
462 D-loop (HVSII) C>T non coding 1 (2) 0 (0) 1 (2,4) 
477 D-loop (HVSII) T>C non coding 2 (3,9) 2 (4,3) 1 (2,4) 
489 D-loop (HVSII) T>C non coding 2 (3,9) 1 (2,2) 1 (2,4) 
497 D-loop (HVSII) C>T non coding 1 (2) 1 (2,2) 1 (2,4) 
499 D-loop (HVSII) G>A non coding 3 (5,9) 3 (6,5) 3 (7,3) 
523/524delAC D-loop (HVSII) del non coding 5 (9,8) 6 (13) 6 (14,6) 
524+AC D-loop (HVSII) ins non coding 1 (2) 1 (2,2) 2 (4,9) 
573+C D-loop (HVSII) ins non coding 1 (2) 1 (2,2) 0 (0) 
573+CCC D-loop (HVSII) ins non coding 1 (2) 1 (2,2) 1 (2,4) 
709 rRNA 12S G>A - 8 (15,7) 5 (10,9) 4 (9,8) 
742 rRNA 12S T>C - 1 (2) 1 (2,2) 1 (2,4) 
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750 rRNA 12S A>G  - 49 (96,1) 44 (95,7) 41 (100) 
769 rRNA 12S G>A - 1 (2) 1 (2,2) 1 (2,4) 
801 rRNA 12S A>G - 1 (2) 0 (0) 1 (2,4) 
930 rRNA 12S G>A - 3 (5,9) 2 (4,3) 1 (2,4) 
960delC rRNA 12S del - 1 (2) 0 (0) 1 (2,4) 
1018 rRNA 12S G>A - 1 (2) 1 (2,2) 1 (2,4) 
1075 rRNA 12S A>G - 0 (0) 1 (2,2) 0 (0) 
1189 rRNA 12S T>C - 1 (2) 0 (0) 0 (0) 
1438 rRNA 12S A>G  - 48 (94,1) 45 (97,8) 40 (97,6) 
1700 rRNA 16S T>C - 2 (3,9) 1 (2,2) 2 (4,9) 
1719 rRNA 16S G>A - 2 (3,9) 1 (2,2) 1 (2,4) 
1721 rRNA 16S C>T - 2 (3,9) 2 (4,3) 2 (4,9) 
1811 rRNA 16S A>G - 6 (11,8) 5 (10,9) 6 (14,6) 
1888 rRNA 16S G>A - 6 (11,8) 5 (10,9) 3 (7,3) 
2083 rRNA 16S T>C - 0 (0) 1 (2,2) 1 (2,4) 
2158 rRNA 16S T>C - 1 (2) 0 (0) 1 (2,4) 
2206 rRNA 16S C>T - 1 (2) 1 (2,2) 1 (2,4) 
2217 rRNA 16S C>T - 1 (2) 0 (0) 0 (0) 
2259 rRNA 16S C>T - 1 (2) 1 (2,2) 1 (2,4) 
2308 rRNA 16S A>G - 1 (2) 1 (2,2) 1 (2,4) 
2392 rRNA 16S T>C - 1 (2) 1 (2,2) 0 (0) 
2416 rRNA 16S T>C - 1 (2) 1 (2,2) 1 (2,4) 
2455 rRNA 16S T>C - 0 (0) 1 (2,2) 0 (0) 
2626 rRNA 16S T>C - 1 (2) 1 (2,2) 1 (2,4) 
2706 rRNA 16S A>G  - 29 (56,9) 25 (54,3) 24 (58,5) 
2707 rRNA 16S A>G  - 1 (2) 1 (2,2) 1 (2,4) 
2789 rRNA 16S C>T - 1 (2) 1 (2,2) 1 (2,4) 
2833 rRNA 16S A>G  - 1 (2) 1 (2,2) 1 (2,4) 
2878et rRNA 16S G+A - 0 (0) 1 (2,2) 0 (0) 
2983et rRNA 16S G+A - 0 (0) 1 (2,2) 0 (0) 
3010 rRNA 16S G>A - 8 (15,7) 7 (15,2) 8 (19,5) 
3197 rRNA 16S T>C - 8 (15,7) 7 (15,2) 7 (17,1) 
3348 NADH dehydrogenase subunit 1 A>G  synonymous 1 (2) 1 (2,2) 1 (2,4) 
3391 NADH dehydrogenase subunit 1 G>A Gly G > Ser S 1 (2) 1 (2,2) 1 (2,4) 
3480 NADH dehydrogenase subunit 1 A>G  synonymous 3 (5,9) 2 (4,3) 2 (4,9) 
3594 NADH dehydrogenase subunit 1 C>T synonymous 1 (2) 1 (2,2) 1 (2,4) 
3672 NADH dehydrogenase subunit 1 A>G  synonymous 1 (2) 1 (2,2) 1 (2,4) 
3742 NADH dehydrogenase subunit 1 C>T synonymous 1 (2) 1 (2,2) 1 (2,4) 
3915 NADH dehydrogenase subunit 1 G>A synonymous 2 (3,9) 2 (4,3) 0 (0) 
3992 NADH dehydrogenase subunit 1 C>T Thr T > Met M 1 (2) 1 (2,2) 1 (2,4) 
4024 NADH dehydrogenase subunit 1 A>G  Thr T > Ala A 1 (2) 1 (2,2) 1 (2,4) 
4104 NADH dehydrogenase subunit 1 A>G  synonymous 1 (2) 1 (2,2) 1 (2,4) 
4136 NADH dehydrogenase subunit 1 A>G  Tyr Y > Cys C 1 (2) 1 (2,2) 1 (2,4) 
4149 NADH dehydrogenase subunit 1 C>T synonymous 1 (2) 1 (2,2) 1 (2,4) 
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4188 NADH dehydrogenase subunit 1 A>G  synonymous 1 (2) 1 (2,2) 1 (2,4) 
4216 NADH dehydrogenase subunit 1 T>C  Tyr Y > His H 8 (15,7) 7 (15,2) 4 (9,8) 
4227 NADH dehydrogenase subunit 1 A>G  synonymous 1 (2) 1 (2,2) 0 (0) 
4227et NADH dehydrogenase subunit 1 A+G synonymous 0 (0) 0 (0) 1 (2,4) 
4277 tRNA isoleucine T>C - 1 (2) 0 (0) 1 (2,4) 
4336 tRNA glutamine T>C - 1 (2) 1 (2,2) 1 (2,4) 
4561 NADH dehydrogenase subunit 2 T>C Val V > Ala A 1 (2) 1 (2,2) 1 (2,4) 
4569et NADH dehydrogenase subunit 2 G+A Glu E > Lys K 1 (2) 0 (0) 0 (0) 
4580 NADH dehydrogenase subunit 2 G>A synonymous 1 (2) 1 (2,2) 0 (0) 
4592 NADH dehydrogenase subunit 2 T>C synonymous 1 (2) 1 (2,2) 1 (2,4) 
4640 NADH dehydrogenase subunit 2 C>A Ile I > Met M 1 (2) 1 (2,2) 1 (2,4) 
4646 NADH dehydrogenase subunit 2 T>C synonymous 2 (3,9) 2 (4,3) 3 (7,3) 
4727 NADH dehydrogenase subunit 2 A>G  synonymous 2 (3,9) 2 (4,3) 0 (0) 
4732 NADH dehydrogenase subunit 2 A>G  Asn N > Ser S 2 (3,9) 2 (4,3) 2 (4,9) 
4745 NADH dehydrogenase subunit 2 A>G  synonymous 1 (2) 1 (2,2) 1 (2,4) 
4769 NADH dehydrogenase subunit 2 A>G  synonymous 49 (96,1) 44 (95,7) 41 (100) 
4772 NADH dehydrogenase subunit 2 T>C synonymous 1 (2) 0 (0) 1 (2,4) 
4793 NADH dehydrogenase subunit 2 A>G  synonymous 1 (2) 1 (2,2) 1 (2,4) 
4811 NADH dehydrogenase subunit 2 A>G  synonymous 1 (2) 1 (2,2) 1 (2,4) 
4824 NADH dehydrogenase subunit 2 A>G  Thr T > Ala A 1 (2) 1 (2,2) 0 (0) 
4843 NADH dehydrogenase subunit 2 C>T Thr T > Met M 1 (2) 1 (2,2) 1 (2,4) 
4917 NADH dehydrogenase subunit 2 A>G  Asn N-Asp D 6 (11,8) 6 (13) 3 (7,3) 
4967 NADH dehydrogenase subunit 2 T>G Ser S > Arg R 0 (0) 0 (0) 1 (2,4) 
5004 NADH dehydrogenase subunit 2 T>C synonymous 1 (2) 1 (2,2) 1 (2,4) 
5081 NADH dehydrogenase subunit 2 T>C synonymous 1 (2) 1 (2,2) 1 (2,4) 
5086 NADH dehydrogenase subunit 2 C>T Thr T > Ile I 1 (2) 1 (2,2) 1 (2,4) 
5130 NADH dehydrogenase subunit 2 T>C synonymous 1 (2) 1 (2,2) 1 (2,4) 
5147 NADH dehydrogenase subunit 2 G>A synonymous 5 (9,8) 4 (8,7) 2 (4,9) 
5153 NADH dehydrogenase subunit 2 A>G  synonymous 1 (2) 1 (2,2) 1 (2,4) 
5187 NADH dehydrogenase subunit 2 C>T  synonymous 1 (2) 1 (2,2) 1 (2,4) 
5231 NADH dehydrogenase subunit 2 G>A synonymous 1 (2) 0 (0) 0 (0) 
5396 NADH dehydrogenase subunit 2 C>T synonymous 2 (3,9) 2 (4,3) 1 (2,4) 
5460 NADH dehydrogenase subunit 2 G>A Ala A > Thr T 4 (7,8) 3 (6,5) 4 (9,8) 
5471 NADH dehydrogenase subunit 2 G>A synonymous 2 (3,9) 1 (2,2) 2 (4,9) 
5495 NADH dehydrogenase subunit 2 T>C synonymous 2 (3,9) 1 (2,2) 2 (4,9) 
5498 NADH dehydrogenase subunit 2 A>G  synonymous 1 (2) 0 (0) 0 (0) 
5568 tRNA tryptophan A>G  - 0 (0) 1 (2,2) 0 (0) 
5633 tRNA alanine C>T - 1 (2) 1 (2,2) 0 (0) 
5656 non-coding nucleotides A>G  - 1 (2) 1 (2,2) 0 (0) 
5824 tRNA tyrosine G>A - 1 (2) 1 (2,2) 1 (2,4) 
5918 Cytochrome c oxidase subunit I  T>C synonymous 1 (2) 1 (2,2) 1 (2,4) 
5964 Cytochrome c oxidase subunit I  T>C synonymous 1 (2) 0 (0) 1 (2,4) 
5999 Cytochrome c oxidase subunit I  T>C synonymous 2 (3,9) 2 (4,3) 3 (7,3) 
6040 Cytochrome c oxidase subunit I  A>G  synonymous 1 (2) 0 (0) 1 (2,4) 
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6047 Cytochrome c oxidase subunit I  A>G  synonymous 2 (3,9) 2 (4,3) 3 (7,3) 
6146 Cytochrome c oxidase subunit I  A>G  synonymous 1 (2) 1 (2,2) 1 (2,4) 
6182 Cytochrome c oxidase subunit I  G>A synonymous 1 (2) 1 (2,2) 1 (2,4) 
6253 Cytochrome c oxidase subunit I  T>C Met M > Thr T 1 (2) 1 (2,2) 0 (0) 
6261 Cytochrome c oxidase subunit I  G>A Ala A > Thr T 1 (2) 1 (2,2) 1 (2,4) 
6392 Cytochrome c oxidase subunit I  T>C synonymous 1 (2) 1 (2,2) 0 (0) 
6413 Cytochrome c oxidase subunit I  T>C synonymous 1 (2) 1 (2,2) 1 (2,4) 
6663 Cytochrome c oxidase subunit I  A>G Ile I > Val V 1 (2) 1 (2,2) 1 (2,4) 
6776 Cytochrome c oxidase subunit I  T>C synonymous 3 (5,9) 3 (6,5) 2 (4,9) 
6911 Cytochrome c oxidase subunit I  T>C synonymous 1 (2) 1 (2,2) 1 (2,4) 
6959 Cytochrome c oxidase subunit I  C>T Gly G > Val V 1 (2) 1 (2,2) 0 (0) 
7028 Cytochrome c oxidase subunit I  C>T  synonymous 27 (52,9) 25 (54,3) 24 (58,5) 
7076 Cytochrome c oxidase subunit I  A>G  synonymous 1 (2) 1 (2,2) 1 (2,4) 
7175 Cytochrome c oxidase subunit I  T>C synonymous 1 (2) 1 (2,2) 1 (2,4) 
7193 Cytochrome c oxidase subunit I  T>C synonymous 1 (2) 1 (2,2) 1 (2,4) 
7256 Cytochrome c oxidase subunit I  C>T synonymous 1 (2) 1 (2,2) 1 (2,4) 
7269 Cytochrome c oxidase subunit I  G>A Val V > Met M 1 (2) 0 (0) 0 (0) 
7274 Cytochrome c oxidase subunit I  C>T synonymous 1 (2) 1 (2,2) 1 (2,4) 
7476 tRNA serine 1 C>T - 1 (2) 1 (2,2) 0 (0) 
7492 tRNA serine 1 C>T - 1 (2) 0 (0) 1 (2,4) 
7521 tRNA aspartic acid G>A - 1 (2) 1 (2,2) 1 (2,4) 
7546 tRNA aspartic acid T>C - 1 (2) 1 (2,2) 1 (2,4) 
7553 tRNA aspartic acid A>G - 0 (0) 0 (0) 1 (2,4) 
7598 Cytochrome c oxidase subunit II G>A Ala A > Thr T 1 (2) 1 (2,2) 1 (2,4) 
7645 Cytochrome c oxidase subunit II T>C synonymous 1 (2) 1 (2,2) 1 (2,4) 
7705 Cytochrome c oxidase subunit II T>C synonymous 1 (2) 1 (2,2) 1 (2,4) 
7768 Cytochrome c oxidase subunit II A>G  synonymous 3 (5,9) 3 (6,5) 2 (4,9) 
7771 Cytochrome c oxidase subunit II A>G  synonymous 1 (2) 1 (2,2) 1 (2,4) 
7789 Cytochrome c oxidase subunit II G>A synonymous 1 (2) 1 (2,2) 1 (2,4) 
7810 Cytochrome c oxidase subunit II C>T synonymous 0 (0) 0 (0) 1 (2,4) 
7861 Cytochrome c oxidase subunit II T>C synonymous 2 (3,9) 1 (2,2) 2 (4,9) 
7873 Cytochrome c oxidase subunit II C>T  synonymous 1 (2) 1 (2,2) 2 (4,9) 
7885 Cytochrome c oxidase subunit II T>C synonymous 1 (2) 1 (2,2) 1 (2,4) 
7912 Cytochrome c oxidase subunit II G>A synonymous 0 (0) 0 (0) 1 (2,4) 
8155 Cytochrome c oxidase subunit II G>A synonymous 1 (2) 1 (2,2) 0 (0) 
8206 Cytochrome c oxidase subunit II G>T Met M > Ile I 1 (2) 2 (4,3) 1 (2,4) 
8251 Cytochrome c oxidase subunit II G>A synonymous 1 (2) 0 (0) 0 (0) 
8269 Cytochrome c oxidase subunit II G>A synonymous 1 (2) 0 (0) 1 (2,4) 
8280+CCCCCTCTA non-coding nucleotides ins - 1 (2) 1 (2,2) 2 (4,9) 
8281delCCCCCTCTA non-coding nucleotides del - 1 (2) 1 (2,2) 0 (0) 
8378 ATP synthase F0 subunit 8 A>G Asn N > Asp D 1 (2) 1 (2,2) 1 (2,4) 
8381 ATP synthase F0 subunit 8 A>G Thr T > Ala A 1 (2) 1 (2,2) 1 (2,4) 
8386 ATP synthase F0 subunit 8 C>T synonymous 1 (2) 1 (2,2) 1 (2,4) 
8412 ATP synthase F0 subunit 8 T>C Met M > Thr T 1 (2) 0 (0) 1 (2,4) 
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8431 ATP synthase F0 subunit 8 C>T synonymous 1 (2) 1 (2,2) 1 (2,4) 
8512 ATP synthase F0 subunit 8 A>G  synonymous 1 (2) 1 (2,2) 1 (2,4) 
8555 ATP synthase F0 subunit 6 T>C Ile I > Thr T 1 (2) 1 (2,2) 1 (2,4) 
8557 ATP synthase F0 subunit 6  G>A Ala NP > Thr P 1 (2) 0 (0) 1 (2,4) 
8642 ATP synthase F0 subunit 6  A>G  Asn N > Ser S 1 (2) 1 (2,2) 1 (2,4) 
8697 ATP synthase F0 subunit 6  G>A synonymous 6 (11,8) 5 (10,9) 3 (7,3) 
8701 ATP synthase F0 subunit 6 A>G  Thr T > Ala A 1 (2) 1 (2,2) 1 (2,4) 
8803 ATP synthase F0 subunit 6 A>T Thr T > Ser S 1 (2) 1 (2,2) 1 (2,4) 
8818 ATP synthase F0 subunit 6 C>T synonymous 0 (0) 0 (0) 1 (2,4) 
8860 ATP synthase F0 subunit 6 A>G  Thr T > Ala A 50 (98) 45 (97,8) 39 (95,1) 
8867 ATP synthase F0 subunit 6 T>C Ile I > Thr T 1 (2) 1 (2,2) 1 (2,4) 
8901 ATP synthase F0 subunit 6 A>G  synonymous 0 (0) 1 (2,2) 0 (0) 
8906et ATP synthase F0 subunit 6 A+G His H > Arg R 0 (0) 1 (2,2) 1 (2,4) 
8938 ATP synthase F0 subunit 6 A>G  Ile I > Val V 1 (2) 1 (2,2) 1 (2,4) 
8953 ATP synthase F0 subunit 6 A>G  Ile I > Val V 1 (2) 1 (2,2) 0 (0) 
9007 ATP synthase F0 subunit 6 A>G  Thr T > Ala A 1 (2) 1 (2,2) 1 (2,4) 
9055 ATP synthase F0 subunit 6 G>A Ala A > Thr T 2 (3,9) 1 (2,2) 2 (4,9) 
9070 ATP synthase F0 subunit 6 T>G Ser S > Ala A 1 (2) 1 (2,2) 1 (2,4) 
9123 ATP synthase F0 subunit 6 G>A synonymous 1 (2) 1 (2,2) 1 (2,4) 
9201 ATP synthase F0 subunit 6 C>T synonymous 1 (2) 1 (2,2) 1 (2,4) 
9221 Cytochrome c oxidase subunit III A>G  synonymous 1 (2) 1 (2,2) 1 (2,4) 
9380 Cytochrome c oxidase subunit III G>A synonymous 3 (5,9) 3 (6,5) 1 (2,4) 
9438 Cytochrome c oxidase subunit III G>A Gly G > Ser S 1 (2) 0 (0) 1 (2,4) 
9477 Cytochrome c oxidase subunit III G>A Val V > Ile I 8 (15,7) 7 (15,2) 7 (17,1) 
9540 Cytochrome c oxidase subunit III T>C synonymous 1 (2) 1 (2,2) 1 (2,4) 
9548 Cytochrome c oxidase subunit III G>A synonymous 1 (2) 1 (2,2) 1 (2,4) 
9621 Cytochrome c oxidase subunit III G>A Ala A > Thr T 1 (2) 1 (2,2) 0 (0) 
9656 Cytochrome c oxidase subunit III T>C synonymous 1 (2) 1 (2,2) 1 (2,4) 
9664 Cytochrome c oxidase subunit III A>G Glu E > Gly G 1 (2) 0 (0) 1 (2,4) 
9667 Cytochrome c oxidase subunit III A>G  Asn N > Ser S 1 (2) 1 (2,2) 1 (2,4) 
9677 Cytochrome c oxidase subunit III C>T synonymous 0 (0) 1 (2,2) 1 (2,4) 
9698 Cytochrome c oxidase subunit III T>C synonymous 3 (5,9) 2 (4,3) 2 (4,9) 
9716 Cytochrome c oxidase subunit III T>C synonymous 2 (3,9) 1 (2,2) 1 (2,4) 
9744et Cytochrome c oxidase subunit III G+A Glu E > Lys K 0 (0) 0 (0) 1 (2,4) 
9770 Cytochrome c oxidase subunit III T>C synonymous 1 (2) 1 (2,2) 1 (2,4) 
9804 Cytochrome c oxidase subunit III G>T Ala A > Ser S 1 (2) 1 (2,2) 1 (2,4) 
9861 Cytochrome c oxidase subunit III T>C Phe F > Leu L 1 (2) 1 (2,2) 1 (2,4) 
9863 Cytochrome c oxidase subunit III C>T synonymous 1 (2) 1 (2,2) 1 (2,4) 
9932 Cytochrome c oxidase subunit III G>A synonymous 1 (2) 1 (2,2) 0 (0) 
10101 Cytochrome c oxidase subunit III T>C synonymous 1 (2) 1 (2,2) 0 (0) 
10115 Cytochrome c oxidase subunit III T>C synonymous 1 (2) 1 (2,2) 1 (2,4) 
10143 Cytochrome c oxidase subunit III G>A Gly G > Ser S 1 (2) 1 (2,2) 1 (2,4) 
10172 Cytochrome c oxidase subunit III G>A synonymous 1 (2) 1 (2,2) 0 (0) 
10202 Cytochrome c oxidase subunit III C>T synonymous 0 (0) 1 (2,2) 0 (0) 
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10217 Cytochrome c oxidase subunit III A>G  synonymous 1 (2) 0 (0) 1 (2,4) 
10218 Cytochrome c oxidase subunit III A>G Lys K > Glu E 0 (0) 1 (2,2) 0 (0) 
10320 Cytochrome c oxidase subunit III G>A Val V > Ile I 1 (2) 1 (2,2) 1 (2,4) 
10365 Cytochrome c oxidase subunit III G>A Ala A > Thr T 1 (2) 0 (0) 0 (0) 
10398 Cytochrome c oxidase subunit III A>G  Thr T > Ala A 4 (7,8) 3 (6,5) 3 (7,3) 
10463 tRNA arginine T>C  - 6 (11,8) 5 (10,9) 3 (7,3) 
10550 
NADH dehydrogenase subunit 
4L  
A>G  - 3 (5,9) 2 (4,3) 2 (4,9) 
10589 
NADH dehydrogenase subunit 
4L  
G>A synonymous 2 (3,9) 2 (4,3) 0 (0) 
10601 
NADH dehydrogenase subunit 
4L  
T>C synonymous 1 (2) 1 (2,2) 1 (2,4) 
10750 
NADH dehydrogenase subunit 
4L  
A>G  Asn N > Ser S 1 (2) 1 (2,2) 1 (2,4) 
10822 NADH dehydrogenase subunit 4  C>T  synonymous 1 (2) 1 (2,2) 1 (2,4) 
10873 NADH dehydrogenase subunit 4 T>C synonymous 0 (0) 1 (2,2) 1 (2,4) 
10907 NADH dehydrogenase subunit 4 T>C Phe F > Leu L 1 (2) 1 (2,2) 1 (2,4) 
10915 NADH dehydrogenase subunit 4 T>C synonymous 1 (2) 1 (2,2) 1 (2,4) 
10931 NADH dehydrogenase subunit 4 T>C Ser S > Pro P 1 (2) 0 (0) 1 (2,4) 
10954 NADH dehydrogenase subunit 4 C>T synonymous 1 (2) 1 (2,2) 1 (2,4) 
10993 NADH dehydrogenase subunit 4 G>A synonymous 1 (2) 1 (2,2) 1 (2,4) 
11009 NADH dehydrogenase subunit 4 T>C synonymous 1 (2) 1 (2,2) 1 (2,4) 
11167 NADH dehydrogenase subunit 4 A>G  synonymous 1 (2) 1 (2,2) 1 (2,4) 
11251 NADH dehydrogenase subunit 4 A>G  synonymous 8 (15,7) 6 (13) 4 (9,8) 
11299 NADH dehydrogenase subunit 4 T>C synonymous 3 (5,9) 2 (4,3) 2 (4,9) 
11332 NADH dehydrogenase subunit 4 C>T synonymous 2 (3,9) 2 (4,3) 3 (7,3) 
11339 NADH dehydrogenase subunit 4 T>C synonymous 1 (2) 1 (2,2) 1 (2,4) 
11467 NADH dehydrogenase subunit 4 A>G  synonymous 14 (27,5) 12 (26,1) 13 (31,7) 
11719 NADH dehydrogenase subunit 4 G>A synonymous 23 (45,1) 18 (39,1) 18 (43,9) 
11812 NADH dehydrogenase subunit 4 A>G  synonymous 5 (9,8) 4 (8,7) 2 (4,9) 
11869 NADH dehydrogenase subunit 4 C>A synonymous 1 (2) 0 (0) 0 (0) 
11914 NADH dehydrogenase subunit 4 G>A synonymous 4 (7,8) 4 (8,7) 3 (7,3) 
11935 NADH dehydrogenase subunit 4 T>C synonymous 1 (2) 1 (2,2) 1 (2,4) 
11944 NADH dehydrogenase subunit 4 T>C  synonymous 1 (2) 1 (2,2) 1 (2,4) 
12007 NADH dehydrogenase subunit 4 G>A synonymous 1 (2) 0 (0) 1 (2,4) 
12061 NADH dehydrogenase subunit 4 C>T synonymous 1 (2) 1 (2,2) 1 (2,4) 
12193 tRNA histidine A>G - 0 (0) 1 (2,2) 0 (0) 
12297 tRNA leucine2 T>C - 1 (2) 1 (2,2) 1 (2,4) 
12308 tRNA leucine2 A>G  - 13 (25,5) 12 (26,1) 13 (31,7) 
12372 NADH dehydrogenase subunit 5 G>A synonymous 14 (27,5) 12 (26,1) 13 (31,7) 
12396 NADH dehydrogenase subunit 5 T>C synonymous 1 (2) 0 (0) 1 (2,4) 
12397 NADH dehydrogenase subunit 5 A>G  Thr T > Ala A 1 (2) 1 (2,2) 1 (2,4) 
12612 NADH dehydrogenase subunit 5 A>T synonymous 2 (3,9) 1 (2,2) 1 (2,4) 
12618 NADH dehydrogenase subunit 5 G>A synonymous 1 (2) 1 (2,2) 1 (2,4) 
12633 NADH dehydrogenase subunit 5 C>A synonymous 1 (2) 1 (2,2) 1 (2,4) 
12693 NADH dehydrogenase subunit 5 A>G  synonymous 1 (2) 1 (2,2) 1 (2,4) 
12705 NADH dehydrogenase subunit 5 C>T synonymous 1 (2) 1 (2,2) 1 (2,4) 
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12738 NADH dehydrogenase subunit 5 T>G synonymous 1 (2) 1 (2,2) 1 (2,4) 
12744 NADH dehydrogenase subunit 5 C>T synonymous 1 (2) 1 (2,2) 0 (0) 
12757 NADH dehydrogenase subunit 5 T>C Phe F > Leu L 1 (2) 1 (2,2) 0 (0) 
12811 NADH dehydrogenase subunit 5 T>C Tyr Y > His H 1 (2) 1 (2,2) 1 (2,4) 
12858 NADH dehydrogenase subunit 5 C>T synonymous 1 (2) 1 (2,2) 1 (2,4) 
13015 NADH dehydrogenase subunit 5 T>C synonymous 1 (2) 1 (2,2) 1 (2,4) 
13308 NADH dehydrogenase subunit 5 A>G synonymous 1 (2) 0 (0) 1 (2,4) 
13348 NADH dehydrogenase subunit 5 A>G Met M > Val V 0 (0) 0 (0) 1 (2,4) 
13368 NADH dehydrogenase subunit 5 G>A synonymous 6 (11,8) 5 (10,9) 3 (7,3) 
13401 NADH dehydrogenase subunit 5 T>C synonymous 1 (2) 1 (2,2) 1 (2,4) 
13434 NADH dehydrogenase subunit 5 A>G  synonymous 1 (2) 1 (2,2) 1 (2,4) 
13449 NADH dehydrogenase subunit 5 C>T synonymous 1 (2) 1 (2,2) 1 (2,4) 
13539 NADH dehydrogenase subunit 5 A>G  synonymous 1 (2) 1 (2,2) 1 (2,4) 
13590 NADH dehydrogenase subunit 5 G>A synonymous 2 (3,9) 2 (4,3) 2 (4,9) 
13617 NADH dehydrogenase subunit 5 T>C synonymous 7 (13,7) 7 (15,2) 7 (17,1) 
13637 NADH dehydrogenase subunit 5 A>G  Gln Q > Arg R 1 (2) 2 (4,3) 2 (4,9) 
13650 NADH dehydrogenase subunit 5 C>T synonymous 1 (2) 1 (2,2) 1 (2,4) 
13680 NADH dehydrogenase subunit 5 C>T synonymous 1 (2) 1 (2,2) 1 (2,4) 
13708 NADH dehydrogenase subunit 5 G>A Ala A > Thr T 2 (3,9) 1 (2,2) 1 (2,4) 
13710 NADH dehydrogenase subunit 5 A>G  synonymous 1 (2) 1 (2,2) 1 (2,4) 
13722 NADH dehydrogenase subunit 5 A>G  synonymous 1 (2) 1 (2,2) 1 (2,4) 
13743 NADH dehydrogenase subunit 5 T>C synonymous 1 (2) 1 (2,2) 1 (2,4) 
13788 NADH dehydrogenase subunit 5 C>A synonymous 1 (2) 1 (2,2) 1 (2,4) 
13803 NADH dehydrogenase subunit 5 A>G  synonymous 1 (2) 1 (2,2) 1 (2,4) 
13827 NADH dehydrogenase subunit 5 A>G  synonymous 1 (2) 1 (2,2) 1 (2,4) 
13879 NADH dehydrogenase subunit 5 T>C Ser S > Pro P 1 (2) 0 (0) 1 (2,4) 
13928 NADH dehydrogenase subunit 5 G>C Ser S > Thr T 1 (2) 1 (2,2) 1 (2,4) 
13938 NADH dehydrogenase subunit 5 C>T synonymous 1 (2) 1 (2,2) 1 (2,4) 
14007 NADH dehydrogenase subunit 5 A>C Trp W < Cys C 1 (2) 0 (0) 1 (2,4) 
14037 NADH dehydrogenase subunit 5 A>G  synonymous 1 (2) 0 (0) 0 (0) 
14094 NADH dehydrogenase subunit 5 T>C synonymous 1 (2) 1 (2,2) 1 (2,4) 
14139 NADH dehydrogenase subunit 5 A>G  synonymous 1 (2) 1 (2,2) 1 (2,4) 
14167 NADH dehydrogenase subunit 6 C>T synonymous 3 (5,9) 2 (4,3) 2 (4,9) 
14180 NADH dehydrogenase subunit 6 T>C Tyr Y > Cys C 1 (2) 0 (0) 0 (0) 
14182 NADH dehydrogenase subunit 6 T>C synonymous 3 (5,9) 3 (6,5) 2 (4,9) 
14220 NADH dehydrogenase subunit 6 A>G  synonymous 0 (0) 1 (2,2) 1 (2,4) 
14233 NADH dehydrogenase subunit 6 A>G  synonymous 5 (9,8) 4 (8,7) 2 (4,9) 
14256 NADH dehydrogenase subunit 6 T>C Ile I > Val V 1 (2) 1 (2,2) 1 (2,4) 
14323 NADH dehydrogenase subunit 6 G>A synonymous 1 (2) 1 (2,2) 1 (2,4) 
14365 NADH dehydrogenase subunit 6 C>T synonymous 0 (0) 1 (2,2) 1 (2,4) 
14410 NADH dehydrogenase subunit 6 G>A Asp D > Asn N 0 (0) 0 (0) 1 (2,4) 
14475 NADH dehydrogenase subunit 6 A>G synonymous 0 (0) 1 (2,2) 0 (0) 
14566 NADH dehydrogenase subunit 6 A>G  synonymous 1 (2) 1 (2,2) 1 (2,4) 
14569 NADH dehydrogenase subunit 6 G>A synonymous 1 (2) 1 (2,2) 1 (2,4) 
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14582 NADH dehydrogenase subunit 6 A>G  Val V > Ala A 1 (2) 1 (2,2) 1 (2,4) 
14620 NADH dehydrogenase subunit 6 C>T synonymous 2 (3,9) 2 (4,3) 3 (7,3) 
14629 NADH dehydrogenase subunit 6 C>T synonymous 0 (0) 1 (2,2) 1 (2,4) 
14696 cytochrome b A>G  synonymous 1 (2) 1 (2,2) 0 (0) 
14766 cytochrome b C>T  synonymous 23 (45,1) 19 (41,3) 17 (41,5) 
14793 cytochrome b A>G  His H > Arg R 5 (9,8) 4 (8,7) 5 (12,2) 
14798 cytochrome b T>C Phe F > Leu L 3 (5,9) 2 (4,3) 2 (4,9) 
14866 cytochrome b C>T synonymous 1 (2) 1 (2,2) 1 (2,4) 
14872 cytochrome b C>T synonymous 1 (2) 1 (2,2) 1 (2,4) 
14905 cytochrome b G>A synonymous 6 (11,8) 5 (10,9) 3 (7,3) 
14944 cytochrome b C>T synonymous 1 (2) 1 (2,2) 0 (0) 
15088 cytochrome b C>T synonymous 1 (2) 1 (2,2) 0 (0) 
15139 cytochrome b T>C synonymous 1 (2) 1 (2,2) 1 (2,4) 
15191 cytochrome b T>C synonymous 1 (2) 1 (2,2) 0 (0) 
15204 cytochrome b T>C Ile I > Thr T 0 (0) 1 (2,2) 1 (2,4) 
15218 cytochrome b A>G  Thr T > Ala A 3 (5,9) 2 (4,3) 3 (7,3) 
14257 cytochrome b G>A Asp D > Asn N 1 (2) 1 (2,2) 0 (0) 
15301 cytochrome b G>A synonymous 1 (2) 1 (2,2) 1 (2,4) 
15315 cytochrome b C>T Ala A > Val V 1 (2) 1 (2,2) 0 (0) 
15323 cytochrome b G>A Ala A > Thr T 1 (2) 1 (2,2) 1 (2,4) 
15326 cytochrome b A>G  Thr T > Ala A 49 (96,1) 45 (97,8) 41 (100) 
15452 cytochrome b C>A  Leu L- Ile I  7 (13,7) 6 (13) 2 (4,9) 
15454 cytochrome b T>C synonymous 1 (2) 1 (2,2) 1 (2,4) 
15458 cytochrome b T>C Ser S > Pro P 2 (3,9) 2 (4,3) 1 (2,4) 
15497 cytochrome b G>A Gly G > Ser S 0 (0) 1 (2,2) 1 (2,4) 
15511 cytochrome b T>C synonymous 1 (2) 1 (2,2) 1 (2,4) 
15602et cytochrome b A+G Asn N > Asp D 0 (0) 0 (0) 1 (2,4) 
15607 cytochrome b A>G  synonymous 6 (11,8) 5 (10,9) 3 (7,3) 
15693 cytochrome b T>C Met M > Thr T 2 (3,9) 2 (4,3) 3 (7,3) 
15784 cytochrome b T>C synonymous 1 (2) 1 (2,2) 1 (2,4) 
15789 cytochrome b C>T Thr T > Ile I 1 (2) 1 (2,2) 1 (2,4) 
15792 cytochrome b T>C Ile I > Thr T 1 (2) 1 (2,2) 1 (2,4) 
15812 cytochrome b G>A Val V > Met M 1 (2) 0 (0) 0 (0) 
15817 cytochrome b A>G synonymous 1 (2) 1 (2,2) 1 (2,4) 
15829 cytochrome b A>G synonymous 1 (2) 1 (2,2) 1 (2,4) 
15833 cytochrome b C>T synonymous 1 (2) 1 (2,2) 1 (2,4) 
15883 cytochrome b G>A synonymous 1 (2) 0 (0) 1 (2,4) 
15904 tRNA threonine C>T - 1 (2) 1 (2,2) 1 (2,4) 
15916 tRNA threonine T>C - 0 (0) 0 (0) 1 (2,4) 
15924 tRNA threonine A>G  - 2 (3,9) 1 (2,2) 2 (4,9) 
15924et tRNA threonine A+G - 1 (2) 0 (0) 0 (0) 
15928 tRNA threonine G>A - 6 (11,8) 5 (10,9) 3 (7,3) 
15930 tRNA threonine G>A - 1 (2) 1 (2,2) 1 (2,4) 
15944delT tRNA threonine del - 1 (2) 1 (2,2) 1 (2,4) 
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15948 tRNA threonine A>G - 0 (0) 0 (0) 1 (2,4) 
16069 D-loop (HVSI) C>T non coding 1 (2) 1 (2,2) 1 (2,4) 
16093 D-loop (HVSI) T>C non coding 2 (3,9) 2 (4,3) 2 (4,9) 
16114 D-loop (HVSI) C>A non coding 1 (2) 1 (2,2) 1 (2,4) 
16126 D-loop (HVSI) T>C  non coding 8 (15,7) 6 (13) 4 (9,8) 
16129 D-loop (HVSI) G>A non coding 1 (2) 1 (2,2) 1 (2,4) 
16145 D-loop (HVSI) G>A non coding 2 (3,9) 0 (0) 1 (2,4) 
16147 D-loop (HVSI) C>T non coding 1 (2) 1 (2,2) 1 (2,4) 
16153 D-loop (HVSI) G>A non coding 1 (2) 1 (2,2) 0 (0) 
16163 D-loop (HVSI) A>G  non coding 1 (2) 1 (2,2) 0 (0) 
16166delA D-loop (HVSI) del non coding 1 (2) 1 (2,2) 1 (2,4) 
16169 D-loop (HVSI) C>T non coding 0 (0) 0 (0) 1 (2,4) 
16172 D-loop (HVSI) T>C  non coding 2 (3,9) 2 (4,3) 1 (2,4) 
16179 D-loop (HVSI) C>A non coding 1 (2) 0 (0) 1 (2,4) 
16184 D-loop (HVSI) C>T  non coding 1 (2) 0 (0) 1 (2,4) 
16187 D-loop (HVSI) C>T non coding 1 (2) 0 (0) 1 (2,4) 
16189 D-loop (HVSI) T>C  non coding 5 (9,8) 4 (8,7) 3 (7,3) 
16192 D-loop (HVSI) C>T non coding 2 (3,9) 2 (4,3) 2 (4,9) 
16193 D-loop (HVSI) C>T non coding 1 (2) 1 (2,2) 0 (0) 
16213 D-loop (HVSI) G>A non coding 1 (2) 1 (2,2) 1 (2,4) 
16217 D-loop (HVSI) T>C non coding 1 (2) 1 (2,2) 1 (2,4) 
16222 D-loop (HVSI) C>T non coding 1 (2) 0 (0) 1 (2,4) 
16223 D-loop (HVSI) C>T non coding 1 (2) 1 (2,2) 1 (2,4) 
16224 D-loop (HVSI) T>C  non coding 3 (5,9) 2 (4,3) 2 (4,9) 
16256 D-loop (HVSI) C>T non coding 6 (11,8) 5 (10,9) 6 (14,6) 
16261 D-loop (HVSI) C>T  non coding 2 (3,9) 1 (2,2) 2 (4,9) 
16264et D-loop (HVSI) C+T non coding 0 (0) 0 (0) 1 (2,4) 
16265 D-loop (HVSI) A>T non coding 1 (2) 1 (2,2) 0 (0) 
16266 D-loop (HVSI) C>T  non coding 1 (2) 1 (2,2) 1 (2,4) 
16270 D-loop (HVSI) C>T  non coding 7 (13,7) 5 (10,9) 6 (14,6) 
16274 D-loop (HVSI) G>A non coding 1 (2) 1 (2,2) 1 (2,4) 
16278 D-loop (HVSI) C>T  non coding 1 (2) 1 (2,2) 1 (2,4) 
16286 D-loop (HVSI) C>T  non coding 1 (2) 1 (2,2) 1 (2,4) 
16291 D-loop (HVSI) C>T  non coding 1 (2) 1 (2,2) 1 (2,4) 
16294 D-loop (HVSI) C>T  non coding 9 (17,6) 8 (17,4) 6 (14,6) 
16295 D-loop (HVSI) C>T  non coding 1 (2) 0 (0) 0 (0) 
16295et D-loop (HVSI) C+T non coding 0 (0) 0 (0) 1 (2,4) 
16296 D-loop (HVSI) C>T  non coding 2 (3,9) 2 (4,3) 1 (2,4) 
16298 D-loop (HVSI) T>C  non coding 3 (5,9) 4 (8,7) 4 (9,8) 
16304 D-loop (HVSI) T>C  non coding 6 (11,8) 3 (6,5) 4 (9,8) 
16305 D-loop (HVSI) A>G  non coding 1 (2) 1 (2,2) 1 (2,4) 
16309 D-loop (HVSI) A>G  non coding 1 (2) 1 (2,2) 1 (2,4) 
16311 D-loop (HVSI) T>C  non coding 6 (11,8) 6 (13) 4 (9,8) 
16324 D-loop (HVSI) T>C  non coding 1 (2) 1 (2,2) 0 (0) 
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16325 D-loop (HVSI) T>C  non coding 0 (0) 1 (2,2) 1 (2,4) 
16336 D-loop (HVSI) G>A non coding 1 (2) 1 (2,2) 0 (0) 
16343 D-loop (HVSI) A>G  non coding 1 (2) 1 (2,2) 1 (2,4) 
16352 D-loop (HVSI) T>C  non coding 1 (2) 1 (2,2) 1 (2,4) 
16356 D-loop (HVSI) T>C  non coding 2 (3,9) 2 (4,3) 3 (7,3) 
16362 D-loop (HVSI) T>C  non coding 5 (9,8) 5 (10,9) 3 (7,3) 
16390 D-loop (HVSI) G>A non coding 2 (3,9) 2 (4,3) 2 (4,9) 
16399 D-loop (HVSI) A>G  non coding 3 (5,9) 2 (4,3) 3 (7,3) 
16482 D-loop (HVSI) A>G  non coding 2 (3,9) 2 (4,3) 0 (0) 
16497 D-loop (HVSI) A>G  non coding 1 (2) 0 (0) 1 (2,4) 
16519 D-loop T>C  non coding 21 (41,2) 21 (45,7) 15 (36,6) 
16526 D-loop G>A non coding 2 (3,9) 2 (4,3) 2 (4,9) 
Table 4: Mutations relative to the revised Cambridge Reference Sequences (rCRS) found in 138 complete mtDNA 
sequences from DS, DSM and DSS subjects. (1) Novel mutations are underlined and in italics. (2) Mutations 
resulting in an aminoacid change are in bold. 
 
 
We found that there are three novel mutations in DS subjects (two of them non synonymous), eight 
are in DSM subjects (one of them non synonymous) and eight are in DSS subjects (five of them non 
synonymous) but the comparison is not statistically significant. 
We wondered whether in DS subjects there is a specific region of the mtDNA more prone to 
accumulation of mutations with respect to DSS or DSM subjects. We therefore studied the position of the 
mutations along the mtDNA genome (Table 5) and we found that the mutations accumulate equally in the 
three groups analyzed, even if the total number of mutations between DS, DSM and DSS subjects is 
statistically significant. 
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mtDNA 
region 
N. 
mutations 
in DS 
N. 
mutations 
in DSM 
N. 
mutations 
in DSS 
Fisher-
exact test 
DS-DSM 
Fisher-
exact test 
DS-DSS 
Fisher- 
exact test 
DSM-DSS 
D-loop 291 253 229 p=0.9232 p=0.8047 p=0.9186 
ND1 25 23 18 p=0.8849 p=0.7583 p=0.6389 
ND2 95 82 75 p=0.8759 p=0.829 p=0.9751 
ND4L 7 6 4 p=0.9629 p=0.7636 p=0.7555 
ND4 73 60 59 p=0.7209 p=0.9968 p=0.7767 
ND5 66 57 59 p=0.9263 p=0.6433 p=0.5663 
ND6 19 20 18 p=0.9629 p=0.7392 p=0.7452 
COI 52 47 46 p=0.9182 p=0.6785 p=0.8318 
COII 16 14 16 p=0.9884 p=1 p=0.5849 
COIII 40 35 31 p=0.9818 p=0.9037 p=0.901 
ATPase6 70 64 57 p=0.8585 p=0.9707 p=0.9253 
ATPase8 6 5 6 p=0.9629 p=1 p=0.7664 
cyt b 122 110 93 p=0.8898 p=0.7184 p=0.6049 
rRNA total 188 166 154 p=0.9743 p=0.9531 p=0.9518 
tRNA total 40 35 34 p=0.9818 p=0.9054 p=0.9025 
NC(1) 3 3 2 p=1 p=0.8323 p=1 
Total 1113 980 901 p=0.003647 p=0.06853 p=0.0002313 
Table 5: Number of mutations found along the mtDNA molecule regions in DS, DSM and DSS subjects and Fisher-
exact test values in pairs. (1) Non Coding nucleotides. 
 
 
 
As expected, D-loop is the region that has more variable sites, following by NADH dehydrogenase, 
rRNAs, cytochrome b, cytochrome c oxidase, ATPase, tRNAs. 
Sporadic mutations (present in one sample only) are found in 15 DS, 16 DSS and 12 DSM subjects 
(Table 6). Even though this difference is not significant (Fisher-exact test, p-value=0.4497), it is very 
interesting to notice how mutations accumulate in each group. DS subjects have 5 non coding mutations, 5 
synonymous mutations and 5 non-synonymous mutations. These mutations, changing the aminoacid 
sequence, hit NADH dehydrogenase subunits (2 and 6), cytochrome c (subunit I and III) and cytochrome b. 
At the same time, in DSS subjects we found also 7 non coding mutations, 4 synonymous mutations and 5 
non-synonymous mutations, that hit NADH dehydrogenase subunits (2, 5 and 6), cytochrome c (subunit III) 
and cytochrome b. DSM subjects have, instead, different mutations in different positions: 1 non-
synonymous mutation (cytochrome c subunit III), 8 non coding mutations and 3 synonymous mutations.  
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SPORADIC MUTATIONS 
mtDNA 
region 
N. mutations 
in DS 
N. mutations 
in DSM 
N. mutations 
in DSS 
D-loop 2 2 4 
ND1 0 0 1 
ND2 3 0 1 
ND4L 0 0 0 
ND4 1 0 0 
ND5 1 0 1 
ND6 1 1 1 
COI 1 0 0 
COII 1 0 2 
COIII 1 2 1 
ATPase6 0 1 1 
ATPase8 0 0 0 
cyt b 1 0 1 
rRNA total 2 4 0 
tRNA total 1 2 3 
NC(1) 0 0 0 
Total 15 12 16 
Table 6: sporadic mutations found along mtDNA molecule regions in DS, DSM and DSS 
subjects. (1) Non Coding nucleotides. 
 
We have also analyzed the percentage of non-synonymous mutations of each DS subject and 
compared with their cognitive scores in order to evaluate any significant association. We have found a 
negative trend, i.e. at increasing the scores of total, verbal and performance IQ decreases the percentage 
of non-synonymous mutations. 
 
 
4. Analysis of heteroplasmy 
We analyzed mtDNA CR heteroplasmy in a 300 bp strecht (nt 16531-261), surrounding the 150 
position. 
In order to quantify the levels of heteroplasmy in the biological samples under study, we applied 
DHPLC to artificial heteroplasmic samples and assembled the reference curve that was used for estimating 
the levels of heteroplasmy in the biological samples. 
The distribution of the levels of heteroplasmy in the three groups (Figure 4) shows that most of the 
samples display 0% of heteroplasmy, 92.45% of DS, 87.23% of DSM and 92.68% of DSS, respectively. 
Moreover, figure 4 shows that approximately 4% of DS subjects and 2% of both DSM and DSS subjects 
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have levels of heteroplasmy lower than 2.5%. Levels of heteroplasmy between 2.5%-5% are present only 
in both DSM and DSS (2.13% and 2.44% respectively), while 2% of both DS and DSS and 8% of DSM 
have an heteroplasmy between 5%-10%. Finally only one DS subject has a heteroplasmy at 33%. 
 
 
Figure 4: distribution of the levels of heteroplasmy in DS, DSM and DSS subjects. 
 
The number of heteroplasmic samples is so low that any other correlation, such as with mtDNA 
haplogroups or haplotype, resulted not statistically significant. 
 
 
5. APOE genotype 
We determined the APOE genotype and the corresponding allele frequencies in the three groups 
under study. As expected APOE ε3/ε3 is the most common genotype in all samples. In particular we found 
any DS subject with two ε4 allele, 10 (18,87%) with at least one ε4 allele and 43 (81.13%) without ε4 allele; 
in DSM group we found respectively 0%, 21.28% and 78.72%; in DSS subjects we found respectively 
4.88%, 19.51% and 75.61%. 
The number of subjects, the respective percentage for each of the six genotypes and the allele 
frequencies for DS, DSM and DSS, estimated by counting alleles and compared with those previously 
reported in literature [Mahley and Rall, 2000], are shown in Table 7. 
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Genotype DS N=53 (%) DSM N=47 (%) DSS N=41 (%)  
ε2/ε2 0 (0) 2 (4,26) 0 (0)  
ε2/ε3 6 (11,32) 4 (8,51) 4 (9,76)  
ε3/ε3 37 (69,81) 31 (65,96) 27 (65,85)  
ε2/ε4 0 (0) 2 (4,26) 1 (2,44)  
ε3/ε4 10 (18,87) 8 (17,02) 7 (17,07)  
ε4/ε4 0 (0) 0 (0) 2 (4,88)  
Alleles DS N=106 (%) DSM N=92 (%) DSS N=82 (%) Reference (*) (%) 
ε2 6 (5,7) 10 (10,9) 5 (6,1) 6,6 
ε3 90 (84,9) 72 (78,3) 65 (79,3) 84,8 
ε4 10 (9,4) 10 (10,9) 12 (14,6) 8,2 
(*) Mahley and Rall, 2000 
Table 7: Comparison of the six different APOE genotypes, and of the allelic frequencies between 
DS patients and DSM and DSS and compared with those reported by Mahley and Rall, 
2000. 
 
The distribution of our sample by group, gender and APOE4 status (Table 8) showed no significant 
difference. 
 
  
DS (N=53) DSM (N=47) DSS (N=41) 
Female 
 
(N=27) (N=47) (N=28) 
Age (years) (mean ± SD) 27.0 ± 14.9 56.9 ± 9.5 32.1 ± 14.4 
APOE4 status APOE4+ 18.5% 23.4% 28.6% 
 
APOE4- 81.5% 76.6% 71.4% 
Male 
 
(N=26) (N=0) (N=13) 
Age (years) (mean ± SD) 29.6 ± 9.9 0 28.4 ± 9.6 
APOE4 status APOE4+ 19.2% 0% 15.4% 
 
APOE4- 80.8% 0% 84.6% 
Table 8: Characteristics of the study participants subdivided by group, gender and APOE4 status. 
 
We have also matched the macro-haplogroups with APOE4 status (Figure 5) in order to identify the 
potential sub-haplogroup associated with Down Syndrome. We found no significant differences between 
the three groups under study. 
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Figure 5:Distribution of macro-haplogroups by APOE4 status. 
 
Analyzing the three groups separately, we can see some haplogroups statistically associated with 
APOE4 status (Table 9). In particular, in DS subjects haplogroups K is statistically associated with the 
absence of ε4 allele (OR = 0.0, 95% C.I.= 0.0-0.67), also in DSS subjects, haplogroups K is statistically 
associated with the APOE4- (OR = 0.0, 95%C.I. = 0.0-0.83). In DSM groups the haplogroups statistically 
significant are HV*, associated with APOE4-, and T, associated with APOE4+, (OR = 0.45, 95%C.I. = 0.24-
0.81 and OR = 4.89, 95%C.I. = 2.03-13.13). Finally, in DSS subjects also haplogroup T is statistically 
significant (OR = 8.01, 95%C.I. = 2.26-43.62) and associated with the presence of APOE ε4 allele. 
 
 
APOE4- vs APOE4+ 
 
DS DSM DSS 
mtDNA 
macro-
haplogroups 
p-value OR 95%C.I. p-value OR 95%C.I. p-value OR 95%C.I. 
HV* 0.5712 0.81 0.45-1.48 0.00706 0.45 0.24-0.81 0.5673 1.23 0.67-2.24 
J 0.05938 0.0 0.0-1.07 0.2462 0.0 0.0-2.41 0.2462 0.0 0.0-2.41 
T 0.1165 1.99 0.84-5.02 0.0000356 4.89 2.03-13.13 0.000224 8.01 2.26-43.62 
K 0.01402 0.0 0.0-0.67 0.05938 0.0 0.0-1.07 0.02893 0.0 0.0-0.83 
U 0.1941 1.61 0.81-3.25 0.1941 1.61 0.81-3.25 0.1881 0.61 0.30-1.23 
Other 0.4975 0.0 0.0-5.32 0.2462 0.0 0.0-2.41 0.2462 0.0 0.0-2.41 
Table 9: Fisher exact test (p-value), Odds ratio and 95% Confidence Intervals for macro-haplogroups associated with 
APOE4 status. 
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In order to evaluate if ε4 might correlate with the mental retardation, we analysed the APOE4 status 
with the cognitive scores of the DS subjects. In fact 47 DS subjects were carefully evaluated for their 
cognitive status and we got access to these data; 37 subjects (mean age 32, SD 13.5) have no ε4 allele 
and 10 subjects (mean age 25, SD 8.3) have at least one ε4 allele. All subjects had full IQ value < 65 
points. The two DS subgroups were not statistically different in mean total IQ (TIQ), verbal IQ (VIQ) and 
performance IQ (PIQ) values (Table 10). 
 
 APOE4- (N=37) APOE4+ (N=10) 
TIQ 44.4 ± 14.7 43.6 ± 17.0 
VIQ 47.8 ± 15.7 46.6 ± 17.7 
PIQ 46.8 ± 15.3 45.6 ± 17.7 
Table 10: neuropsychological profile of DS subjects, subdivided by 
APOE4 status. 
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Chapter 7 
 
DISCUSSION AND CONCLUSIONS 
 
 
Down Syndrome (DS) is defined as a genetic disorder in which multiple major aspects of the 
senescent phenotype appear. In fact, it has been shown that most features of physiological aging such as 
skin and hair changes, visual and hearing impairments, thyroid dysfunction, diabetes, obesity, immune and 
central nervous systems changes [Esbensen, 2010] appear in DS earlier than in karyotypically normal age-
matched subjects. In particular, adults with DS experience a decline of cognitive function which is reported 
to be in many cases an Alzheimer-like dementia, as well as an altered free radical metabolism and 
impaired mitochondrial function that lead to neuronal degeneration from 30-35 years of age onwards – 
thirty to forty years earlier than in the normal population. [Lott et al. 2001; Busciglio et al. 2002 and 2007; 
Haan et al. 2003],  
It is thought that the oxidative stress, resulting from an imbalance in the metabolism of free radicals 
such as reactive oxygen species (ROS), have a direct role in the development of neuropathological 
changes of AD in DS [Kedziora and Bartosz, 1988; Busciglio et al. 1998]. Predisposing factors such as 
aging, DS, or gene mutations associated with familial AD contribute by either increasing oxidative stress 
[Carney J and Carney A, 1994] or Aβ production and deposition [Selkoe, 1997], which impairs 
mitochondrial function, resulting in energy depletion followed by further neuronal degeneration [Flint Beal, 
1992]. 
Mitochondria are the most susceptible target of ROS formation and mutations in the mtDNA control 
region occur in demented individuals with DS [Coskun et al. 2010]. 
In the present study, we investigated an integrated set of molecular genetic parameters (sequencing 
of complete mtDNA, heteroplasmy of the mtDNA control region, genotypes of APOE gene) in order to 
identify a possible association with the early neurocognitive decline observed in DS. 
 
 
1. mtDNA analysis 
Previous reports have suggested that mtDNA mutations have a role in the pathogenesis and 
aetiology of DS [Arbuzova, 1995, 1996; 1998 and 2002]. In particular three new point mutations were found 
in the complete mtDNA sequence of three DS individuals in the following genes: ATP-ase (G8764A) and 
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ND5 (G13243A) with the same aminoacid substitutions Ala/Thr, and ND1 (G3337A) with aminoacid 
substitution Val/Met; Arbuzova hypothesized that these mtDNA mutations explain the association of DS 
with premature ageing and diabetes, which are more common in the mothers of DS individuals. 
Furthermore mtDNA is entirely of maternal origin, as is the extra chromosome 21 in the majority of DS 
cases, and examination of pedigrees from families with aneuploidy recurrence indicates cytoplasmic 
inheritance as a risk factor [Arbuzova, 2002]. In this regard, it was shown that in amniocytes of DS fetuses 
decreased ATPase6 gene expression during oocyte meiotic maturation reduces the capacity for oxidative 
phosphorylation and influences ATP generation, leading to chromosomal nondisjunction [Lee et al. 2003]. 
Coskun et al. (2010) support the hypothesis that mitochondrial dysfunction is a major factor in the 
age related dementia associated with advanced age DS patients. In fact, they observed a high frequency of 
mtDNA regulatory control region homoplasmic and heteroplasmic mutations in the brains of AD and DS 
and dementia patients. These mutations would be expected to affect mtDNA replication and L-strand 
transcription, following by reduction in the mtDNA copy number and an overall decline in OXPHOS. These 
reductions would result in reduced mitochondrial energy output, increased mitochondrial ROS production, 
reduced mitochondrial membrane potential and thus altered calcium regulation, and an increased 
probability for the activation of the mtPTP, predisposing neurons to loss of processes and ultimately death. 
Our database is the first of this kind in the literature because it compares DS subjects with their 
mothers and siblings matched for age and gender. So we can be sure that any mutations found in the DS 
subjects would be typical of the syndrome or maternally inherited. 
In our DS subjects we found 19 novel mutations in DS subjects (seven of them non-synonymous), 
but the same SNPs were also found in the complete mtDNA sequences of mothers and siblings. Only two 
novel mutations (het4569, 10365) are DS specific, of which one is non-synonymous. Comparing the 
number of mutations along mtDNA molecule by mtDNA regions, we found that the mutations accumulate 
equally in the three groups analyzed and even when we analyzed the sporadic mutations (showing up in 
one sample only), the DS, DSM and DSS groups under study resulted balanced. We hypothesize that 
oxidative stress, documented in DS, does not depend firstly by specific mtDNA mutations, but rather by a 
general dysfunction of mitochondria, involving the antioxidant systems. 
Michikawa et al. (1999) reported that some mutations in the CR, such as T414G, T408A, A189G, 
accumulate with age in specific tissues, but most recently a C150T mutation has been identified in 
lymphocytes of centenarians and twins [Zhang et al. 2003]. This study is of great value because it indicates 
a possible beneficial effect on longevity by a mtDNA somatic mutation able to restore the mitochondrial 
replication machinery. In this regard, Rose et al. (2007 and 2010) argued that the patterns of mtDNA CR 
heteroplasmy do not differ between centenarians and their descendants, but differ between relatives of 
centenarians and age-matched controls, in which heteroplasmy is lower. Therefore it seems that mtDNA 
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CR heteroplasmy is genetically controlled and that it overcomes the age-related mitochondrial dysfunction 
with mitochondria complementation. 
Rose et al. were the first to compare the levels of heteroplasmy between relatives, but there are 
many reports [Meierhofer et al. 2005; Irwin et al. 2009; Sondheimer et al. 2011] which, analyzing the 
heteroplasmy with other methods, as well as DHPLC, have demonstrated that different sites and portions 
of the control region exhibit greatly different levels of population variation and rates of phylogenetic 
sequence evolution. Moreover, Sondheimer et al. (2011), examining mother-child pairs, found that 
heteroplasmy was inherited for the 30% and for the 70%, occur de novo in offspring or, conversely, be 
present in mothers but eliminated in their children. 
Most of our samples do not display heteroplasmy, (92.45% of DS, 87.23% of DSM and 92.68% of 
DSS, respectively). Approximately 4% of DS subjects and 2% of both DSM and DSS subjects have levels 
of heteroplasmy lower than 2.5%. Levels of heteroplasmy between 2.5%-5% are present only in both DSM 
and DSS (2.13% and 2.44% respectively), while 2% of both DS and DSS and 8% of DSM have an 
heteroplasmy between 5%-10%. Finally only one DS subject has an heteroplasmy at 33%. Our data are in 
the same direction of previous reports since we observe an upward trend in the levels of heteroplasmy with 
age in DS and DSS groups, but there is no correlation in the members of the same family, except for two 
families: in one there is correlation between DS and DSM, in the other the correlation is between DSM and 
DSS. So it seems that heteroplasmy accumulates because of stochastic events. 
 
 
2. APOE genotypes analysis 
We have already said that DS subjects are characterized by a dementia Alzheimer-like, with also 
neuropathological characteristics of AD. The recognized genetic risk factor for developing AD is 
represented by the presence of APOE ε4 allele; however, several studies [Lott, 1992; Wisniewski et al. 
1995] have demonstrated that the development of pathological changes in DS does not always parallel that 
observed in AD patients and that the ε4 allele frequency is the same between the AD-DS cases and DS 
controls [Val Gool et al. 1995]; on the contrary, others studies found that demented adults with DS showed 
a significantly higher frequency of ε4 allele compared to non-demented adults [Deb et al. 2000]. 
Within our sample we have observed that DS patients do not differ in terms of APOE alleles 
frequency neither from the general population nor from DSM and DSS subjects. It can be hypothesized that 
the early neurocognitive decline of DS subjects depends on the overexpression of the other proteins 
encoded by Chr 21, such as APP (amyloid precurson protein), that is the precursor of Aβ and consequently 
determines the formation of senile plaques. 
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Furthermore, there is large amount of evidence about the role of mitochondria in the pathogenesis of 
AD even if several studies reported lack of association between mtDNA haplogroups and AD [van der Walt 
et al. 2005; Mancuso et al. 2007], while others found positive associations [van der Walt et al. 2004; 
Maruszak et al. 2009; Santoro et al. 2010]. In our samples we found that haplogroup T appears to be 
associated with APOE ε4 allele in the three groups analyzed; nevertheless the amount of our samples is 
too low for considering reliable this result. 
 
Summarizing, with the present work we aimed at identifying genetic determinants of Down 
Syndrome. Specifically, the major objectives were the following: 
1. to analyze the mtDNA from a quantitative and qualitative perspective, in order to argue if it 
can be considered risk factor for the DS decline; 
2. to genotype APOE gene, in order to evaluate ε4 allele and its association with the DS 
cognitive status. 
In conclusion, our study highlighted that mtDNA somatic mutations (either in heteroplasmy or 
homoplasmy) does not play a role in the development of AD-like dementia in our sample of DS subjects, 
that was bona fide present in 9 subjects (scoring in the stage of profound cognitive impairment according to 
IQ assessment – for instance indicated as score 19). We could exclude also that these subjects were 
bringing the APOE4 allele more frequently than those who scored higher. 
Probably, the analysis of mitochondria is the correct way to understand the complex traits of Down 
Syndrome; nevertheless studies should focus on the mitochondrial functionality and/or on another tissue 
other than whole blood. 
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APPENDIX 
 
 
TBE 10X (TRIS BORATO EDTA) 1L 
108 gr TRIS BASE 
55 gr boric acid 
40 ml EDTA 0.5X pH=8 
 
TBE 1X 1L 
100 ml TBE 10X 
900 ml distilled H2O  
 
AGAROSE GEL 0.8 %, 1.5%, 2% IN TBE 1X 250 ML (it changes only the amount of agarose) 
250 ml TBE 1X 
2.0 gr, 3.75 gr, 5.0 gr agarose 
12.5 ml Gel Red staining (5 μl in 100 ml) 
 
MS AGAROSE GEL 4.5% IN TBE 1X 250 ML 
250 ml TBE 1X 
11.25 gr MS agarose 
12.5 ml Gel Red staining (5 μl in 100 ml) 
 
NaAc 
P.M.=82.03 g/moli 
A final concetration of 3M pH=4.6. 
Moles= 3M*0.2 l=0.6 moles 
Grams= 0.6 moli*82.03 g/moles=49.218g 
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PRIMERS FOR COMPLETE mtDNA AMPLIFICATION 
 
Name  Start (5’) End (5’) Length  Primer Fw  Primer Rv  
38 16187 275 657 5'  TGT AAA ACG ACG GCC AGT CCT CCC CAT GCT TAC A   3' 5'  CAG GAA ACA GCT ATG ACC  CTG TGT GGA AAG CGG  3' 
22 6 503 497 5'  TGT AAA ACG ACG GCC AGT CAG GTC TAT CAC CCT  ATT    3' 5'  CAG GAA ACA GCT ATG ACC GGG TTG TAT TGA TGA GAT TA  3‘ 
39 318 927 609 5'  TGT AAA ACG ACG GCC AGT TGG CCA CAG CAC TTA AAC  3' 5'  CAG GAA ACA GCT ATG ACC CTA TTG ACT TGG GTT AAT CG  3' 
21 720 1074 354 5'  TGT AAA ACG ACG GCC AGT CCC GTT CCA GTG AGT T  3' 5'  CAG GAA ACA GCT ATG ACC CCC AGT TTG GGT CTT AG   3' 
31 873 1431 558 5'  TGT AAA ACG ACG GCC AGT GGT TGG TCA ATT TCG TGC  3' 5'  CAG GAA ACA GCT ATG ACC CTG CTA AAT CCA CCT TCG  3' 
18 1174 1770 596 5'  TGT AAA ACG ACG GCC AGT TGG CGG TGC TTC ATA TC  3' 5'  CAG GAA ACA GCT ATG ACC CGC CAG GTT TCA ATT TCT 3' 
1 1485 2078 593 5'  TGT AAA ACG ACG GCC AGT GCC CGT CAC CCT C   3' 5'  CAG GAA ACA GCT ATG ACC GGG ATT TAG AGG GTT CT 3'  
2 1873 2441 568 5'  TGT AAA ACG ACG GCC AGT AAC TTT GCA AGG AGA GCC  3' 5'  CAG GAA ACA GCT ATG ACC  GCA TGC CTG TGT TGG   3' 
3 2201 2797 596 5'  TGT AAA ACG ACG GCC AGT GCG TTC AAG CTC AAC AC 3' 5'  CAG GAA ACA GCT ATG ACC GCA GGT TTG GTA GTT TAG  3'  
4 2571 3170 599 5'  TGT AAA ACG ACG GCC AGT GCG GTA CCC TAA CCG   3' 5'  CAG GAA ACA GCT ATG ACC GGG AAG GCG CTT TGT  3' 
23 2927 3527 600 5'  TGT AAA ACG ACG GCC AGT CCC TAG GGA TAA CAG 3' 5'  CAG GAA ACA GCT ATG ACC GCG GTG ATG TAG AGG   3' 
5 3306 3890 584 5'  TGT AAA ACG ACG GCC AGT CAT ACC CAT GGC CAA C  3' 5'  CAG GAA ACA GCT ATG ACC CGG TTG GTC TCT GC  3' 
24 3640 4167 527 5'  TGT AAA ACG ACG GCC AGT CCT CTA GCC TAG CCG   3' 5'  CAG GAA ACA GCT ATG ACC GTG TAT GAG TTG GTC GTA   3' 
40 3897 4533 636 5'  TGT AAA ACG ACG GCC AGT CTT CGA CCT TGC CGA A  3' 5'  CAG GAA ACA GCT ATG ACC GCG CTG TGA TGA GTG T 3' 
25 4389 4987 598 5'  TGT AAA ACG ACG GCC AGT CAC CCC ATC CTA AAG TAA   3' 5'  CAG GAA ACA GCT ATG ACC GTT TGG TTT AAT CCA CCT CAA 3' 
41b 4851 5484 633 5'  TGT AAA ACG ACG GCC AGT CTG CTT CTT CTC ACA TGA  3' 5'  CAG GAA ACA GCT ATG ACC TAG GTA GGA GTA GCG TG  3' 
26 5261 5930 669 5'  TGT AAA ACG ACG GCC AGT GGC CAT TAT CGA AGA ATT C 3' 5'  CAG GAA ACA GCT ATG ACC AGA GAA TAG TCA ACG GTC  3' 
27 5696 6263 567 5'  TGT AAA ACG ACG GCC AGT CAG CTA AGC ACC CTA ATC  3' 5'  CAG GAA ACA GCT ATG ACC GGC CTC CAC TAT AGC A  3' 
28 5995 6537 542 5'  TGT AAA ACG ACG GCC AGT CAG CTC TAA GCC TCC T  3' 5'  CAG GAA ACA GCT ATG ACC CTG TTA GTA GTA TAG TGA TG  3' 
42 6425 6892 467 5'  TGT AAA ACG ACG GCC AGT TGC CAT AAC CCA ATA CCA  3' 5'  CAG GAA ACA GCT ATG ACC CTT CCG TGG AGT GTG 3' 
43b 6791 7398 607 5'  TGT AAA ACG ACG GCC AGT ATC AAT TGG CTT CCT AGG  3' 5'  CAG GAA ACA GCT ATG ACC GGC ATC CAT ATA GTC ACT  3' 
29 7233 7805 572 5'  TGT AAA ACG ACG GCC AGT CCC GAT GCA TAC ACC 3' 5'  CAG GAA ACA GCT ATG ACC CTA GGA TGA TGG CGG G 3' 
44b 7681 8274 593 5'  TGT AAA ACG ACG GCC AGT CCT TAT CTG CTT CCT AGT   3' 5'  CAG GAA ACA GCT ATG ACC GGG TGC TAT AGG GTA AAT  3' 
19 8161 8671 510 5'  TGT AAA ACG ACG GCC AGT CTA CGG TCA ATG CTC TG  3' 5'  CAG GAA ACA GCT ATG ACC GTC ATT GTT GGG TGG TG 3' 
30 8533 9060 527 5'  TGT AAA ACG ACG GCC AGT GAA AAT CTG TTC GCT TCA TT  3' 5'  CAG GAA ACA GCT ATG ACC GGT GGC GCT TCC AAT T   3' 
6 8775 9336 561 5'  TGT AAA ACG ACG GCC AGT CCT CCT CGG ACT CC   3' 5'  CAG GAA ACA GCT ATG ACC TGA GGA GCG TTA TGG AG  3' 
16 9046 9642 596 5'  TGT AAA ACG ACG GCC AGT ATT GGA AGC GCC ACC C  3' 5'  CAG GAA ACA GCT ATG ACC AGG TGA TTG ATA CTC CTG 3' 
32 9443 10005 562 5'  TGT AAA ACG ACG GCC AGT CGA TAC GGG ATA ATC CT 3' 5'  CAG GAA ACA GCT ATG ACC TTA TAC TAA AAG AGT AAG ACC C 3' 
33 9751 10280 529 5'  TGT AAA ACG ACG GCC AGT CGA GTC TCC CTT CAC 3' 5'  CAG GAA ACA GCT ATG ACC GGG TAA AAG GAG GGC A 3' 
45b 10121 10724 603 5'  TGT AAA ACG ACG GCC AGT ATT TTG ACT ACC ACA ACT CA  3' 5'  CAG GAA ACA GCT ATG ACC ATA TGT GTT GGA GAT TGA GA  3' 
7 10657 11237 580 5'  TGT AAA ACG ACG GCC AGT TAC TAG TCT TTG CCG CC 3' 5'  CAG GAA ACA GCT ATG ACC GGG GAA GGG AGC CTA  3' 
8 10999 11595 596 5'  TGT AAA ACG ACG GCC AGT CCA ACG CCA CTT ATC C 3' 5'  CAG GAA ACA GCT ATG ACC TGT CGT AGG CAG ATG G 3' 
34 11368 11934 566 5'  TGT AAA ACG ACG GCC AGT CTT ATG ACT CCC TAA AGC 3' 5'  CAG GAA ACA GCT ATG ACC GTG ATA TTT GAT CAG GAG AA  3' 
35 11754 12194 440 5'  TGT AAA ACG ACG GCC AGT CAA ACT ACG AAC GCA CTC 3' 5'  CAG GAA ACA GCT ATG ACC GTC GTA AGC CTC TGT TG 3' 
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17 12007 12560 553 5'  TGT AAA ACG ACG GCC AGT GGG CTC ACT CAC CCA 3' 5'  CAG GAA ACA GCT ATG ACC TGG GTT GTT TGG GTT G 3' 
9 12395 12994 599 5'  TGT AAA ACG ACG GCC AGT TTA CCA CCC TCG TTA ACC 3' 5'  CAG GAA ACA GCT ATG ACC TGC TAG GAG GAG GC 3' 
36 12787 13346 559 5'  TGT AAA ACG ACG GCC AGT CCT TCT TGC TCA TCA GTT 3' 5'  CAG GAA ACA GCT ATG ACC GCT TTG AAG AAG GCG TG 3' 
10 13198 13712 514 5'  TGT AAA ACG ACG GCC AGT GCA GCA GTC TGC GC 3' 5'  CAG GAA ACA GCT ATG ACC GCT GCC AGG CGT TTA A 3' 
46 13515 14124 609 5'  TGT AAA ACG ACG GCC AGT CCA CAT CAT CGA AAC CG 3' 5'  CAG GAA ACA GCT ATG ACC GAT GAG TGG GAA GAA GAA 3' 
11 13802 14373 571 5'  TGT AAA ACG ACG GCC AGT CAG CCC TCG CTG TC 3' 5'  CAG GAA ACA GCT ATG ACC GGA TTG GTG CTG TGG G 3' 
20 14224 14811 587 5'  TGT AAA ACG ACG GCC AGT ACG CCC ATA ATC ATA CAA AG 3' 5'  CAG GAA ACA GCT ATG ACC GGG AGG TCG ATG AAT G 3' 
12 14453 15051 598 5'  TGT AAA ACG ACG GCC AGT GCC ATC GCT GTA GTA TAT 3' 5'  CAG GAA ACA GCT ATG ACC AGG CCT CGC CCG AT 3' 
13 14860 15455 595 5'  TGT AAA ACG ACG GCC AGT CGC CTG CCT GAT CC 3' 5'  CAG GAA ACA GCT ATG ACC GAA GGA AGA GAA GTA AGC 3' 
14 15257 15812 555 5'  TGT AAA ACG ACG GCC AGT GAC AGT CCC ACC CTC 3' 5'  CAG GAA ACA GCT ATG ACC GGA TGC TAC TTG TCC 3' 
15 15608 16185 577 5'  TGT AAA ACG ACG GCC AGT CTA GGA GGC GTC CTT G 3' 5'  CAG GAA ACA GCT ATG ACC GGT TTT GAT GTG GAT TGG 3' 
37 15960 16548 588 5'  TGT AAA ACG ACG GCC AGT AGA AAA AGT CTT TAA CTC CAC 3' 5'  CAG GAA ACA GCT ATG ACC GGG AAC GTG TGG GC 3' 
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REDESIGNED PRIMERS FOR LONG PCR 
 
Name Start (5’) End (5’) Length Primer Fw primer lenght Tm %GC 
7b 10610 11334 724 AAC CCT CAA CAC CCA C 16 46 56,3 
20b 14222 14897 675 CAA CGC CCA TAA TCA TAC 18 46 44,4 
26c 5311 5990 679 TCA TAG CCA CCA TCA CC 17 47 51 
27b 5690 6360 670 AGT TAA CAG CTA AGC ACC C 19 49 48 
45c 10128 10830 702 CTA CCA CAA CTC AAC GG 17 47 52 
47 245 965 720 TTG AAT GTC TGC ACA GCC 18 48 50 
482F 482 1180 698 TCA TCA ATA CAA CCC CCG 18 48 50 
3113F 3113 3798 685 ATT CCT CCC TGT ACG AA 17 45 47,1 
3316F 3316 4020 704 GCC AAC CTC CTA CTC CT 17 49 58,8 
4143F 4143 4840 697 ATT CCG CTA CGA CCA ACT 18 48 50 
4897F 4897 5573 676 ACC AAA TCT CTC CCT CA 17 45 47,1 
5807F 5807 6450 643 ATG AAA ATC ACC TCG GAG C 19 49 47,4 
7706F 7706 8372 666 GCC CTT TTC CTA ACA CTC 18 48 50 
14985F 14985 15637 652 GCT ACC TTC ACG CCA AT 17 47 52 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
91 
 
SUB-HAPLOGROUP OF EACH FAMILY RECRUITED 
Family (N=37) Family (N=10) Family (N=4) Family (N=2) 
DS-DSM-
DSS 
Sub-
Haplogroup 
DS-DSM 
Sub-
Haplogroup 
DS-DSS 
Sub-
Haplogroup 
DS 
Sub-
Haplogroup 
1 V 17 H2a2 27 J1b1a 1047 K2a 
2 H2a2a 24 H2a2a 41 H5a1 1053 T2b 
3 K1a 25 H6a1 45 U5a1a1 
  
4 U5b2a 31 T2b 49 H5b 
  
5 HV0 32 H2a2a 
    
6 H1 33 J2b1 
    
7 U4b1a1 34 H3 
    
8 H1 35 T2e1 
    
9 U5a1a1 48 H6a1b 
    
10 H7a1 50 U5b1c 
    
11 H3 
      
12 U4a 
      
13 H 
      
14 H1 
      
15 L2a1 
      
16 U5a2a 
      
18 U3b2 
      
19 H4a 
      
20 T1 
      
21 U5a2b 
      
22 HV2 
      
23 U5a1b 
      
26 T2b3a 
      
28 K2a 
      
29 U4c1a 
      
30 H3 
      
36 T2c1b 
      
37 H1c 
      
38 HV0 
      
39 H14a 
      
40 H1e1 
      
42 H1e2 
      
43 H5a1 
      
44 U5b2a1a 
      
46 HV10 
      
51 H13a1a 
      
52 HV0c 
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